

Anthony E Lang

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7769391/anthony-e-lang-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

987
papers

88,631
citations

142
h-index

273
g-index

1,063
ext. papers

102,958
ext. citations

7.4
avg, IF

8.19
L-index

#	Paper	IF	Citations
987	Neuroimaging Pearls from the MDS Congress Video Challenge. Part 1: Genetic Disorders.. <i>Movement Disorders Clinical Practice</i> , 2022 , 9, 297-310	2.2	0
986	Combining Skin α -Synuclein Real-Time Quaking-Induced Conversion and Circulating Neurofilament Light Chain to Distinguish Multiple System Atrophy and Parkinson's Disease.. <i>Movement Disorders</i> , 2022 ,	7	1
985	Neuroimaging Pearls from the MDS Congress Video Challenge. Part 2: Acquired Disorders.. <i>Movement Disorders Clinical Practice</i> , 2022 , 9, 311-325	2.2	0
984	The second family affected with a PRDM8-related disease.. <i>Neurological Sciences</i> , 2022 , 1	3.5	0
983	Deep Bayesian networks for uncertainty estimation and adversarial resistance of white matter hyperintensity segmentation.. <i>Human Brain Mapping</i> , 2022 ,	5.9	2
982	Common Data Elements to Facilitate Sharing and Re-use of Participant-Level Data: Assessment of Psychiatric Comorbidity Across Brain Disorders.. <i>Frontiers in Psychiatry</i> , 2022 , 13, 816465	5	
981	Longitudinal evaluations of somatosensory-motor inhibition in Dopa-responsive dystonia.. <i>Parkinsonism and Related Disorders</i> , 2022 , 95, 40-46	3.6	0
980	Patterns of Mixed Pathologies in Down Syndrome.. <i>Journal of Alzheimer's Disease</i> , 2022 ,	4.3	1
979	Case of a Man with Hemichorea and Behavioral Changes: "A Red Herring".. <i>Movement Disorders Clinical Practice</i> , 2022 , 9, 501-507	2.2	0
978	Investigating the contribution of white matter hyperintensities and cortical thickness to empathy in neurodegenerative and cerebrovascular diseases.. <i>GeroScience</i> , 2022 , 1	8.9	
977	Spastic Paraplegia Type 7 and Movement Disorders: Beyond the Spastic Paraplegia.. <i>Movement Disorders Clinical Practice</i> , 2022 , 9, 522-529	2.2	0
976	The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy.. <i>Movement Disorders</i> , 2022 ,	7	19
975	Nomenclature of Genetic Movement Disorders: Recommendations of the International Parkinson and Movement Disorder Society Task Force - An Update.. <i>Movement Disorders</i> , 2022 , 37, 905-935	7	3
974	Levodopa challenge test: indications, protocol, and guide. <i>Journal of Neurology</i> , 2021 , 268, 3135-3143	5.5	16
973	Differences in Drug Pharmacokinetics and Motor Fluctuation in DYT-. <i>Canadian Journal of Neurological Sciences</i> , 2021 , 48, 734-736	1	
972	Identical twins with progressive kyphoscoliosis and ophthalmoplegia. <i>Parkinsonism and Related Disorders</i> , 2021 , 92, 119-122	3.6	
971	Evaluating dopamine transporter imaging as an enrichment biomarker in a phase 2 Parkinson's disease trial. <i>BMC Neurology</i> , 2021 , 21, 459	3.1	3

970	Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary: A Report of the AAN Guideline Subcommittee. <i>Neurology</i> , 2021 , 97, 942-957	6.5	11
969	Mendelian Randomisation Study of Smoking, Alcohol, and Coffee Drinking in Relation to Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2021 ,	5.3	3
968	Probiotics for Constipation in Parkinson Disease: A Randomized Placebo-Controlled Study. <i>Neurology</i> , 2021 , 96, e772-e782	6.5	29
967	Fosmetpantotate Randomized Controlled Trial in Pantothenate Kinase-Associated Neurodegeneration. <i>Movement Disorders</i> , 2021 , 36, 1342-1352	7	9
966	Call the Plumber: Impaired Meningeal Lymphatic Drainage in Parkinson's Disease. <i>Movement Disorders</i> , 2021 , 36, 1125	7	0
965	Proprioceptive recalibration following implicit visuomotor adaptation is preserved in Parkinson's disease. <i>Experimental Brain Research</i> , 2021 , 239, 1551-1565	2.3	4
964	Reply to: "The Logic and Pitfalls of Parkinson's as Brain- Versus Body-First Subtypes". <i>Movement Disorders</i> , 2021 , 36, 786-787	7	1
963	Dream Enactment Behavior Disorder Associated with Pallido-Nigro-Luysian Degeneration and Tau Proteinopathy. <i>Movement Disorders Clinical Practice</i> , 2021 , 8, 594-599	2.2	1
962	The Logic and Pitfalls of Parkinson's Disease as "Brain-First" Versus "Body-First" Subtypes. <i>Movement Disorders</i> , 2021 , 36, 594-598	7	11
961	Teaching Video NeuroImage: "Weighing" in on an Unusual Tremor. <i>Neurology</i> , 2021 , 97, e970-e971	6.5	
960	Exacerbation of Stiff Person Syndrome by Selective Serotonin Reuptake Inhibitors. <i>Movement Disorders Clinical Practice</i> , 2021 , 8, 772-774	2.2	0
959	Preferences for Communication About End-of-Life Care in Atypical Parkinsonism. <i>Movement Disorders</i> , 2021 , 36, 2116-2125	7	0
958	Parkinsonism as a Sequela of SARS-CoV-2 Infection: Pure Hypoxic Injury or Additional COVID-19-Related Response?. <i>Movement Disorders</i> , 2021 , 36, 1483-1484	7	7
957	Expectations of Benefit in a Trial of a Candidate Disease-Modifying Treatment for Parkinson Disease. <i>Movement Disorders</i> , 2021 , 36, 1964-1967	7	1
956	Periodic Alternating Gaze Deviation Due to Paraneoplastic Cerebellar Degeneration. <i>Movement Disorders Clinical Practice</i> , 2021 , 8, 791-793	2.2	0
955	Spinocerebellar Ataxia 40: Another Etiology Underlying Essential Tremor Syndrome. <i>Movement Disorders Clinical Practice</i> , 2021 , 8, 944-946	2.2	3
954	Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease. <i>Annals of Neurology</i> , 2021 , 90, 76-88	9.4	9
953	Multimodal Longitudinal Neurophysiological Investigations in Dopa-Responsive Dystonia. <i>Movement Disorders</i> , 2021 , 36, 1986-1987	7	0

952	A Novel COVID Era-Related Oromandibular Dyskinesia: Surgical Mask-Induced Dyskinesia?. <i>Canadian Journal of Neurological Sciences</i> , 2021 , 1-2	1	1
951	Hyperglycemic hemichorea presenting with normal MRI and striatal hyperdensity on CT. <i>Neurological Sciences</i> , 2021 , 42, 4341-4343	3.5	
950	Movement Disorders Associated with Hypogonadism. <i>Movement Disorders Clinical Practice</i> , 2021 , 8, 997-1011	0	
949	Exposure to Phosphoglycerate Kinase 1 Activators and Incidence of Parkinson's Disease. <i>Movement Disorders</i> , 2021 , 36, 2419-2425	7	1
948	Inhaled Levodopa as a Potential Treatment for Diphasic Dyskinesia. <i>Movement Disorders</i> , 2021 , 36, 265-266		
947	Comparison of Patient and Expert Perceptions of the Attainment of Research Milestones in Parkinson's Disease. <i>Movement Disorders</i> , 2021 , 36, 171-177	7	1
946	A Distinct EEG Marker of Celiac Disease-Related Cortical Myoclonus. <i>Movement Disorders</i> , 2021 , 36, 999-1005	3	
945	Gut Microbial Ecosystem in Parkinson Disease: New Clinicobiological Insights from Multi-Omics. <i>Annals of Neurology</i> , 2021 , 89, 546-559	9.4	34
944	DYT-TUBB4A (DYT4 Dystonia): New Clinical and Genetic Observations. <i>Neurology</i> , 2021 , 96, e1887-e1897	5	1
943	Suggestibility as a valuable criterion for laboratory-supported definite functional movement disorders. <i>Clinical Neurophysiology Practice</i> , 2021 , 6, 103-108	3.8	1
942	Botulinum Toxin-Associated Prolonged Remission of Idiopathic Cervical Dystonia. <i>Canadian Journal of Neurological Sciences</i> , 2021 , 1-5	1	0
941	Improved Segmentation of the Intracranial and Ventricular Volumes in Populations with Cerebrovascular Lesions and Atrophy Using 3D CNNs. <i>Neuroinformatics</i> , 2021 , 19, 597-618	3.2	5
940	Parkinson's Disease and COVID-19: Do We Need to Be More Patient?. <i>Movement Disorders</i> , 2021 , 36, 277	7	5
939	Bilingualism in Parkinson's disease: Relationship to cognition and quality of life. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2021 , 43, 199-212	2.1	1
938	Is clinical assessment enough? Moving towards early differentiation of neurodegenerative parkinsonisms. <i>Brain</i> , 2021 , 144, 1040-1042	11.2	0
937	Neither a Novel Tau Proteinopathy nor an Expansion of a Phenotype: Reappraising Clinicopathology-Based Nosology. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	3
936	MRI-visible perivascular space volumes, sleep duration and daytime dysfunction in adults with cerebrovascular disease. <i>Sleep Medicine</i> , 2021 , 83, 83-88	4.6	2
935	Neuropsychiatric disorders and COVID-19. <i>Lancet Psychiatry</i> , 2021 , 8, 564-565	23.3	1

934	Short-term deceleration capacity of heart rate: a sensitive marker of cardiac autonomic dysfunction in idiopathic Parkinson's disease. <i>Clinical Autonomic Research</i> , 2021 , 31, 729-736	4.3	0
933	Irreversible extreme freezing of gait after dopamine agonist withdrawal. <i>Clinical Case Reports (discontinued)</i> , 2021 , 9, e04712	0.7	0
932	The Discovery of α -Synuclein in Lewy Pathology of Parkinson's Disease: The Inspiration of a Revolution. <i>Movement Disorders Clinical Practice</i> , 2021 , 8, 1189-1193	2.2	1
931	Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. <i>Nature Medicine</i> , 2021 , 27, 1451-1457	50.5	16
930	Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 326, 926-939	27.4	16
929	Contribution of rare variant associations to neurodegenerative disease presentation. <i>Npj Genomic Medicine</i> , 2021 , 6, 80	6.2	1
928	Association of apolipoprotein E variation with cognitive impairment across multiple neurodegenerative diagnoses. <i>Neurobiology of Aging</i> , 2021 , 105, 378.e1-378.e9	5.6	1
927	Abnormal brain structure mediates the association between ApoE4 and slow gait among patients with pathological cognitive impairment: Results from the Ontario Neurodegenerative Research Initiative. <i>Alzheimer's and Dementia</i> , 2020 , 16, e044540	1.2	
926	Phenotype differences between corticobasal syndrome and progressive supranuclear palsy with and without Alzheimer's disease biomarkers. <i>Alzheimer's and Dementia</i> , 2020 , 16, e046071	1.2	
925	Neuroimaging Advances in Parkinson's Disease and Atypical Parkinsonian Syndromes. <i>Frontiers in Neurology</i> , 2020 , 11, 572976	4.1	16
924	Age-Related Parkinsonian Signs in Microdeletion 22q11.2. <i>Movement Disorders</i> , 2020 , 35, 1239-1245	7	2
923	The evidence for multidisciplinary care in Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2020 , 20, 539-549	4.3	3
922	Movement Disorders and Renal Diseases. <i>Movement Disorders Clinical Practice</i> , 2020 , 7, 763-779	2.2	4
921	Parkinson's Disease, NOTCH3 Genetic Variants, and White Matter Hyperintensities. <i>Movement Disorders</i> , 2020 , 35, 2090-2095	7	8
920	Forecasts for the Attainment of Major Research Milestones in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020 , 10, 1047-1055	5.3	3
919	GDNF and Parkinson's Disease: Where Next? A Summary from a Recent Workshop. <i>Journal of Parkinson's Disease</i> , 2020 , 10, 875-891	5.3	28
918	Opinions and clinical practices related to diagnosing and managing functional (psychogenic) movement disorders: changes in the last decade. <i>European Journal of Neurology</i> , 2020 , 27, 975-984	6	25
917	Initiation of pharmacological therapy in Parkinson's disease: when, why, and how. <i>Lancet Neurology</i> , 2020 , 19, 452-461	24.1	51

916	Outcome measurement in functional neurological disorder: a systematic review and recommendations. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020 , 91, 638-649	5.5	37
915	PET Tau Imaging and Motor Impairments Differ Between Corticobasal Syndrome and Progressive Supranuclear Palsy With and Without Alzheimer's Disease Biomarkers. <i>Frontiers in Neurology</i> , 2020 , 11, 574	4.1	5
914	Movement Disorders Due to Selective Basal Ganglia Lesions with Uremia. <i>Canadian Journal of Neurological Sciences</i> , 2020 , 47, 350-365	1	4
913	Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?. <i>Neurology</i> , 2020 , 94, 481-494	6.5	60
912	Author response: Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. <i>Neurology</i> , 2020 , 94, 144-145	6.5	1
911	Mild dopa-responsive dystonia in heterozygous tyrosine hydroxylase mutation carrier: Evidence of symptomatic enzyme deficiency?. <i>Parkinsonism and Related Disorders</i> , 2020 , 71, 44-45	3.6	3
910	Mild dopa-responsive dystonia in heterozygous tyrosine hydroxylase mutation carrier: Evidence of symptomatic enzyme deficiency? Response from the authors. <i>Parkinsonism and Related Disorders</i> , 2020 , 74, 80	3.6	2
909	Adult-onset neuronal intranuclear inclusion disease mimicking Fragile X-associated tremor-ataxia syndrome in ethnic Chinese patients. <i>Parkinsonism and Related Disorders</i> , 2020 , 74, 25-27	3.6	7
908	Isolated Ear Clicks with Partial Voluntary Control. <i>Tremor and Other Hyperkinetic Movements</i> , 2020 , 10, 55	2	
907	Diagnosing functional neurological disorder: seeing the whole picture. <i>CNS Spectrums</i> , 2020 , 1-8	1.8	2
906	Integrated Therapy for Functional Movement Disorders: Time for a Change. <i>Movement Disorders Clinical Practice</i> , 2020 , 7, 169-174	2.2	12
905	Interhemispheric pathways in agenesis of the corpus callosum and Parkinson's disease. <i>Brain Stimulation</i> , 2020 , 13, 360-362	5.1	2
904	Hallucinations, Delusions and Impulse Control Disorders in Parkinson Disease. <i>Clinics in Geriatric Medicine</i> , 2020 , 36, 105-118	3.8	13
903	Late-Onset Mitochondrial Membrane Protein-Associated Neurodegeneration With Extensive Brain Iron Deposition. <i>Movement Disorders Clinical Practice</i> , 2020 , 7, 120-121	2.2	3
902	Recurrent neurologic symptoms complicating venom immunotherapy in a patient with systemic mastocytosis and severe Hymenoptera allergy. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020 , 8, 780-782	5.4	1
901	Outcome Measures for Functional Neurological Disorder: A Review of the Theoretical Complexities. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2020 , 32, 33-42	2.7	33
900	Video-tutorial for the Movement Disorder Society criteria for progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2020 , 78, 200-203	3.6	4
899	The Cortical Basal ganglia Functional Scale (CBFS): Development and preliminary validation. <i>Parkinsonism and Related Disorders</i> , 2020 , 79, 121-126	3.6	4

898	"Opening" New Insights Into LRRK2 Conformation and the Microtubule. <i>Movement Disorders</i> , 2020 , 35, 2162-2163	7	
897	Value of Clinical Signs in Identifying Patients with Scans without Evidence of Dopaminergic Deficit (SWEDD). <i>Journal of Parkinson's Disease</i> , 2020 , 10, 1561-1569	5.3	3
896	Nonsteroidal Anti-inflammatory Use and LRRK2 Parkinson's Disease Penetrance. <i>Movement Disorders</i> , 2020 , 35, 1755-1764	7	21
895	Initiating pharmacotherapy in early Parkinson's disease. <i>Lancet Neurology</i> , 2020 , 19, 643-644	24.1	
894	The retina as a window to the basal ganglia: Systematic review of the potential link between retinopathy and hyperkinetic disorders in diabetes. <i>Parkinsonism and Related Disorders</i> , 2020 , 80, 194-198	3.6	5
893	Cognitive impairment in Parkinson's disease: Associations between subjective and objective cognitive decline in a large longitudinal study. <i>Parkinsonism and Related Disorders</i> , 2020 , 80, 127-132	3.6	3
892	Twinkle-associated familial parkinsonism with Lewy pathology: Cause or predisposition?. <i>Neurology</i> , 2020 , 95, 644-647	6.5	5
891	Telemedicine in Movement Disorders: Lessons du COVID-19. <i>Movement Disorders</i> , 2020 , 35, 1893-1896	7	16
890	Helicobacter pylori Eradication in Parkinson's Disease: A Randomized Placebo-Controlled Trial. <i>Movement Disorders</i> , 2020 , 35, 2250-2260	7	20
889	Reply to: "A New Day: The Role of Telemedicine in Reshaping Care for Persons With Movement Disorders". <i>Movement Disorders</i> , 2020 , 35, 1903-1904	7	6
888	Tongue Protrusion Dystonia in Pantothenate Kinase-Associated Neurodegeneration. <i>Pediatric Neurology</i> , 2020 , 103, 76-78	2.9	3
887	Validation of the movement disorder society criteria for the diagnosis of 4-repeat tauopathies. <i>Movement Disorders</i> , 2020 , 35, 171-176	7	23
886	What Is the Role of a Specialist Assessment Clinic for FND? Lessons From Three National Referral Centers. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2020 , 32, 79-84	2.7	25
885	Primary brain calcification due to a homozygous MYORG mutation causing isolated paroxysmal kinesigenic dyskinesia. <i>Brain</i> , 2020 , 143, e36	11.2	6
884	Reply to "Studying reproducibility of data-driven Parkinson's disease subtypes". <i>Parkinsonism and Related Disorders</i> , 2019 , 66, 245-246	3.6	
883	Orthostatic hypotension and dementia incidence: links and implications. <i>Neuropsychiatric Disease and Treatment</i> , 2019 , 15, 2181-2194	3.1	10
882	Increased markers of cardiac vagal activity in leucine-rich repeat kinase 2-associated Parkinson's disease. <i>Clinical Autonomic Research</i> , 2019 , 29, 603-614	4.3	7
881	Beyond the synucleinopathies: alpha synuclein as a driving force in neurodegenerative comorbidities. <i>Translational Neurodegeneration</i> , 2019 , 8, 28	10.3	42

880	Tics and functional tic-like movements: Can we tell them apart?. <i>Neurology</i> , 2019 , 93, 750-758	6.5	45
879	Cortical GABAergic dysfunction underlying abnormal hand movements in ARX mutation. <i>Clinical Neurophysiology</i> , 2019 , 130, 1750-1751	4.3	0
878	Randomized Delayed-Start Trial of Levodopa in Parkinson's Disease. <i>New England Journal of Medicine</i> , 2019 , 380, 315-324	59.2	145
877	Diagnostic delay in Parkinson's disease caused by PRKN mutations. <i>Parkinsonism and Related Disorders</i> , 2019 , 63, 217-220	3.6	11
876	Genetic Variation in the Ontario Neurodegenerative Disease Research Initiative. <i>Canadian Journal of Neurological Sciences</i> , 2019 , 46, 491-498	1	5
875	Bioinformatics-Based Identification of Expanded Repeats: A Non-reference Intronic Pentamer Expansion in RFC1 Causes CANVAS. <i>American Journal of Human Genetics</i> , 2019 , 105, 151-165	11	80
874	Treatment of Palatal Tremor. <i>Current Clinical Neurology</i> , 2019 , 179-183	0.1	1
873	Gelastic Cataplexy in Niemann Pick Type C. <i>Movement Disorders Clinical Practice</i> , 2019 , 6, 498-499	2.2	
872	Parkinson's disease in the Western Pacific Region. <i>Lancet Neurology</i> , 2019 , 18, 865-879	24.1	55
871	The clinical significance of lower limb tremors. <i>Parkinsonism and Related Disorders</i> , 2019 , 65, 165-171	3.6	5
870	Hiding in Plain Sight: Functional Neurological Disorders in the News. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2019 , 31, 361-367	2.7	11
869	Dystonia and Parkinson's disease: What is the relationship?. <i>Neurobiology of Disease</i> , 2019 , 132, 104462	7.5	37
868	Paroxysmal Asymmetric Dystonic Arm Posturing-A Less Recognized but Characteristic Manifestation of ATP1A3-related disease. <i>Movement Disorders Clinical Practice</i> , 2019 , 6, 312-315	2.2	11
867	Isolated Abdominal Motor Seizures of Mesial Parietal Origin: Epileptic Belly Dancing?. <i>Movement Disorders Clinical Practice</i> , 2019 , 6, 396-399	2.2	2
866	Jumping to overcome freezing of gait while turning in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019 , 64, 349-351	3.6	2
865	Tremor with congenital mirror movements: evidence of involvement of the primary motor cortex in tremor. <i>European Journal of Neurology</i> , 2019 , 26, e66-e67	6	
864	A critique of the second consensus criteria for multiple system atrophy. <i>Movement Disorders</i> , 2019 , 34, 975-984	7	44
863	The Parkinson's disease e-diary: Developing a clinical and research tool for the digital age. <i>Movement Disorders</i> , 2019 , 34, 676-681	7	28

862	How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. <i>Movement Disorders</i> , 2019 , 34, 1228-1232	7	56
861	The Waiting Room: neurological observations made outside the movement disorder specialist's consulting office. <i>Practical Neurology</i> , 2019 , 19, 295-301	2.4	4
860	Diffuse Brain Calcification, a Novel SLC20A2 Variant, Vertical Supranuclear Gaze Palsy, and Systemic Lupus Erythematosus. <i>Movement Disorders Clinical Practice</i> , 2019 , 6, 403-405	2.2	0
859	Successful spinal cord stimulation for severe medication-refractory restless legs syndrome. <i>Movement Disorders</i> , 2019 , 34, 585-586	7	3
858	Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. <i>Neurology</i> , 2019 , 92, 329-337	6.5	144
857	Repurposing drugs to treat l-DOPA-induced dyskinesia in Parkinson's disease. <i>Neuropharmacology</i> , 2019 , 147, 11-27	5.5	18
856	The Movement disorder associated with NMDAR antibody-encephalitis is complex and characteristic: an expert video-rating study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019 , 90, 724-726	5.5	48
855	Single-pulse subthalamic deep brain stimulation reduces premotor-motor facilitation in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019 , 66, 224-227	3.6	3
854	Amantadine for Gait Dysfunction in Pantothenate Kinase-Associated Neurodegeneration. <i>Canadian Journal of Neurological Sciences</i> , 2019 , 46, 782-784	1	2
853	Dancing Dorsal Quadrilaterals-Organic or Functional?-Reply. <i>JAMA Neurology</i> , 2019 , 76, 985-986	17.2	
852	Deep brain stimulation in status dystonicus caused by anti-NMDA receptor encephalitis. <i>Parkinsonism and Related Disorders</i> , 2019 , 66, 255-257	3.6	4
851	ADCY5-Related Dyskinesia: Improving Clinical Detection of an Evolving Disorder. <i>Movement Disorders Clinical Practice</i> , 2019 , 6, 512-520	2.2	18
850	Association Between Social Cognition Changes and Resting State Functional Connectivity in Frontotemporal Dementia, Alzheimer's Disease, Parkinson's Disease, and Healthy Controls. <i>Frontiers in Neuroscience</i> , 2019 , 13, 1259	5.1	17
849	Clinical and neural responses to cognitive behavioral therapy for functional tremor. <i>Neurology</i> , 2019 , 93, e1787-e1798	6.5	43
848	Corticobasal degeneration. <i>International Review of Neurobiology</i> , 2019 , 149, 87-136	4.4	12
847	Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations. <i>Parkinsonism and Related Disorders</i> , 2019 , 60, 138-145	3.6	4
846	Dancing Dorsal Quadrilaterals: A Novel Peripherally Induced Movement Disorder. <i>JAMA Neurology</i> , 2019 , 76, 351-354	17.2	8
845	Successful pallidotomy for post-hyperglycemic hemichorea-ballism. <i>Parkinsonism and Related Disorders</i> , 2019 , 61, 228-230	3.6	5

844	Soft signs in movement disorders: friends or foes?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019 , 90, 961-962	5.5	13
843	Decreased pallidal vesicular monoamine transporter type 2 availability in Parkinson's disease: The contribution of the nigropallidal pathway. <i>Neurobiology of Disease</i> , 2019 , 124, 176-182	7.5	10
842	Beta-propeller protein associated neurodegeneration (BPAN); the first report of three patients from Iran with de novo novel mutations. <i>Parkinsonism and Related Disorders</i> , 2019 , 61, 231-233	3.6	6
841	Gut-brain axis and the spread of β -synuclein pathology: Vagal highway or dead end?. <i>Movement Disorders</i> , 2019 , 34, 307-316	7	98
840	Therapeutic trial design for frontotemporal dementia and related disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019 , 90, 412-423	5.5	16
839	Opsoclonus-myoclonus-encephalopathy induced by cefepime. <i>Journal of the Neurological Sciences</i> , 2019 , 396, 33-35	3.2	5
838	Isolated lingual myoclonus in an HIV patient. <i>Parkinsonism and Related Disorders</i> , 2019 , 61, 241-244	3.6	
837	Linaclotide and Prucalopride for Management of Constipation in Patients with Parkinsonism. <i>Movement Disorders Clinical Practice</i> , 2018 , 5, 218-220	2.2	15
836	Clustering of motor and nonmotor traits in leucine-rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study. <i>Movement Disorders</i> , 2018 , 33, 960-965	7	10
835	A 21-Year Retrospective Study of the Toronto Western Hospital Deep Brain Stimulation Cohort. <i>Movement Disorders</i> , 2018 , 33, 850-852	7	3
834	Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease. <i>Journal of Visualized Experiments</i> , 2018 ,	1.6	14
833	Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations. <i>Movement Disorders</i> , 2018 , 33, 660-677	7	174
832	Pallidal deep brain stimulation modulates cortical excitability and plasticity. <i>Annals of Neurology</i> , 2018 , 83, 352-362	9.4	36
831	Infantile-onset hand dystonia with intellectual disability: Clues to mutations. <i>Neurology</i> , 2018 , 90, 333-335	3	3
830	Exacerbation of psychosis triggered by a synthetic cannabinoid in a 70-year-old woman with Parkinson disease. <i>Cmaj</i> , 2018 , 190, E50-E52	3.5	4
829	CLIPPERS: A Treatable Cause of Spastic Ataxia. <i>Movement Disorders Clinical Practice</i> , 2018 , 5, 212-214	2.2	0
828	Ataxia-telangiectasia: A review of movement disorders, clinical features, and genotype correlations. <i>Movement Disorders</i> , 2018 , 33, 1238-1247	7	62
827	What is "essential" about essential tremor? A diagnostic placeholder. <i>Movement Disorders</i> , 2018 , 33, 58-61	28	28

826	Oculogyric crises in PLA2G6 associated neurodegeneration. <i>Parkinsonism and Related Disorders</i> , 2018 , 52, 111-112	3.6	7
825	Functional neurological disorders in Parkinson disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018 , 89, 566-571	5.5	49
824	Impaired emotion processing in functional (psychogenic) tremor: A functional magnetic resonance imaging study. <i>NeuroImage: Clinical</i> , 2018 , 17, 179-187	5.3	50
823	Altered gut microbiome and metabolome in patients with multiple system atrophy. <i>Movement Disorders</i> , 2018 , 33, 174-176	7	34
822	[F]AV-1451 binding to neuromelanin in the substantia nigra in PD and PSP. <i>Brain Structure and Function</i> , 2018 , 223, 589-595	4	29
821	Pantothenate kinase-associated neurodegeneration mimicking Tourette syndrome: a case report and review of the literature. <i>Neurological Sciences</i> , 2018 , 39, 1797-1800	3.5	4
820	Essential tremor plus is more common than essential tremor: Insights from the reclassification of a cohort of patients with lower limb tremor. <i>Parkinsonism and Related Disorders</i> , 2018 , 56, 109-110	3.6	33
819	Reproducibility of data-driven Parkinson's disease subtypes for clinical research. <i>Parkinsonism and Related Disorders</i> , 2018 , 56, 102-106	3.6	42
818	Emotion Detection Deficits and Decreased Empathy in Patients with Alzheimer's Disease and Parkinson's Disease Affect Caregiver Mood and Burden. <i>Frontiers in Aging Neuroscience</i> , 2018 , 10, 120	5.3	34
817	Smoldering Multiple Myeloma Associated Leukoencephalopathy Presenting with Holmes Tremor, Ataxia, and Pyramidal Syndrome. <i>Movement Disorders Clinical Practice</i> , 2018 , 5, 433-435	2.2	1
816	Sleep-related motor and behavioral disorders: Recent advances and new entities. <i>Movement Disorders</i> , 2018 , 33, 1042-1055	7	6
815	Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11.2. <i>Neurology</i> , 2018 , 90, e2059-e2067	6.5	25
814	Diagnostic criteria for camptocormia in Parkinson's disease: A consensus-based proposal. <i>Parkinsonism and Related Disorders</i> , 2018 , 53, 53-57	3.6	22
813	Brain tissue pulsatility is related to clinical features of Parkinson's disease. <i>NeuroImage: Clinical</i> , 2018 , 20, 222-227	5.3	2
812	[F]AV-1451 binding and postmortem pathology of CBD. <i>Movement Disorders</i> , 2018 , 33, 1360-1361	7	4
811	Comment on "Is it Useful to Classify PSP and CBD as Different Disorders?". <i>Movement Disorders Clinical Practice</i> , 2018 , 5, 564-565	2.2	4
810	ADCK3-related Coenzyme Q10 Deficiency: A Potentially Treatable Genetic Disease. <i>Movement Disorders Clinical Practice</i> , 2018 , 5, 635-639	2.2	16
809	Harnessing the power of placebos in movement disorders: Insights from Parkinson's disease in clinical research and practice. <i>Movement Disorders</i> , 2018 , 33, 1195-1203	7	3

808	Movement disorder society criteria for clinically established early Parkinson's disease. <i>Movement Disorders</i> , 2018 , 33, 1643-1646	7	67
807	Validation of the MDS clinical diagnostic criteria for Parkinson's disease. <i>Movement Disorders</i> , 2018 , 33, 1601-1608	7	101
806	Current Concepts in Diagnosis and Treatment of Functional Neurological Disorders. <i>JAMA Neurology</i> , 2018 , 75, 1132-1141	17.2	252
805	Actigraphy Detects Greater Intra-Individual Variability During Gait in Non-Manifesting LRRK2 Mutation Carriers. <i>Journal of Parkinson's Disease</i> , 2018 , 8, 131-139	5.3	7
804	Movement disorders in non-encephalopathic Hashimoto's thyroiditis. <i>Parkinsonism and Related Disorders</i> , 2018 , 55, 141-142	3.6	12
803	Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy. <i>Journal of Neural Transmission</i> , 2018 , 125, 1373-1379	4.3	14
802	Altered body composition, sarcopenia, frailty, and their clinico-biological correlates, in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018 , 56, 58-64	3.6	47
801	Lymphatic vasculature in human dural superior sagittal sinus: Implications for neurodegenerative proteinopathies. <i>Neuroscience Letters</i> , 2018 , 665, 18-21	3.3	22
800	Parkinson Diseases in the 2020s and Beyond: Replacing Clinico-Pathologic Convergence With Systems Biology Divergence. <i>Journal of Parkinson's Disease</i> , 2018 , 8, S59-S64	5.3	38
799	Neurostimulation for Functional Neurological Disorder: Evaluating Longitudinal Neurophysiology. <i>Movement Disorders Clinical Practice</i> , 2018 , 5, 561-563	2.2	4
798	Serum Inflammatory Profile for the Discrimination of Clinical Subtypes in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2018 , 9, 1123	4.1	11
797	Investigating Voice as a Biomarker for Leucine-Rich Repeat Kinase 2-Associated Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2018 , 8, 503-510	5.3	12
796	Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive-enhancing medications. <i>Movement Disorders</i> , 2018 , 33, 1769-1776	7	18
795	Levodopa-induced dyskinesia in Parkinson disease: Current and evolving concepts. <i>Annals of Neurology</i> , 2018 , 84, 797-811	9.4	122
794	Systematic review of movement disorders and oculomotor abnormalities in Whipple's disease. <i>Movement Disorders</i> , 2018 , 33, 1700-1711	7	11
793	Neuropsychiatric expression and catatonia in 22q11.2 deletion syndrome: An overview and case series. <i>American Journal of Medical Genetics, Part A</i> , 2018 , 176, 2146-2159	2.5	13
792	Regulation of myeloid cell phagocytosis by LRRK2 via WAVE2 complex stabilization is altered in Parkinson's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, E5164-E5173	11.5	61
791	Myoclonus-dystonia: classification, phenomenology, pathogenesis, and treatment. <i>Current Opinion in Neurology</i> , 2018 , 31, 484-490	7.1	43

790	Precision medicine for disease modification in Parkinson disease. <i>Nature Reviews Neurology</i> , 2017 , 13, 119-126	15	103
789	Heart rate variability in leucine-rich repeat kinase 2-associated Parkinson's disease. <i>Movement Disorders</i> , 2017 , 32, 610-614	7	14
788	Essential pitfalls in "essential" tremor. <i>Movement Disorders</i> , 2017 , 32, 325-331	7	52
787	Positron emission tomography imaging of tau pathology in progressive supranuclear palsy. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017 , 37, 3150-3160	7.3	38
786	Pedunculopontine nucleus stimulation in progressive supranuclear palsy: a randomised trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017 , 88, 613-616	5.5	16
785	Oculogyric crises: A review of phenomenology, etiology, pathogenesis, and treatment. <i>Movement Disorders</i> , 2017 , 32, 193-202	7	23
784	Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials. <i>Movement Disorders</i> , 2017 , 32, 319-324	7	111
783	AAV1/2-induced overexpression of A53T- β synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease. <i>Acta Neuropathologica Communications</i> , 2017 , 5, 11	7.3	62
782	Adult motor phenotype differentiates Dravet syndrome from Lennox-Gastaut syndrome and links SCN1A to early onset parkinsonian features. <i>Epilepsia</i> , 2017 , 58, e44-e48	6.4	21
781	Which ante mortem clinical features predict progressive supranuclear palsy pathology?. <i>Movement Disorders</i> , 2017 , 32, 995-1005	7	88
780	Common Myths in the Use of Levodopa in Parkinson Disease: When Clinical Trials Misinform Clinical Practice. <i>JAMA Neurology</i> , 2017 , 74, 633-634	17.2	40
779	Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. <i>Movement Disorders</i> , 2017 , 32, 853-864	7	840
778	Prediction of cognition in Parkinson's disease with a clinical-genetic score: a longitudinal analysis of nine cohorts. <i>Lancet Neurology, The</i> , 2017 , 16, 620-629	24.1	98
777	Tremor-Dominant Pantothenate Kinase-associated Neurodegeneration. <i>Movement Disorders Clinical Practice</i> , 2017 , 4, 772-774	2.2	5
776	Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. <i>Lancet Neurology, The</i> , 2017 , 16, 552-563	24.1	209
775	Tracking the course of prodromal Parkinson's disease. <i>Brain</i> , 2017 , 140, 259-262	11.2	3
774	Imaging biomarkers in Parkinson's disease and Parkinsonian syndromes: current and emerging concepts. <i>Translational Neurodegeneration</i> , 2017 , 6, 8	10.3	121
773	Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease. <i>Movement Disorders</i> , 2017 , 32, 893-903	7	21

772	Neuroimaging and clinical features in adults with a 22q11.2 deletion at risk of Parkinson's disease. <i>Brain</i> , 2017 , 140, 1371-1383	11.2	30
771	Parkinson disease. <i>Nature Reviews Disease Primers</i> , 2017 , 3, 17013	51.1	1700
770	Placebos in clinical trials: unravelling a complex phenomenon. <i>Lancet Neurology</i> , 2017 , 16, 28-29	24.1	5
769	Alternating Hemiplegia of Childhood as a New Presentation of Adenylate Cyclase 5-Mutation-Associated Disease: A Report of Two Cases. <i>Journal of Pediatrics</i> , 2017 , 181, 306-308.e1	3.6	19
768	The Ontario Neurodegenerative Disease Research Initiative (ONDRI). <i>Canadian Journal of Neurological Sciences</i> , 2017 , 44, 196-202	1	44
767	Basal ganglia calcification in a case of PKAN. <i>Parkinsonism and Related Disorders</i> , 2017 , 36, 98-99	3.6	7
766	Levodopa and Parkinson Disease-Myths Revisited-Reply. <i>JAMA Neurology</i> , 2017 , 74, 1270-1271	17.2	1
765	Caffeine as symptomatic treatment for Parkinson disease (CafEPD): A randomized trial. <i>Neurology</i> , 2017 , 89, 1795-1803	6.5	69
764	[F]-THK5351 PET Correlates with Topology and Symptom Severity in Progressive Supranuclear Palsy. <i>Frontiers in Aging Neuroscience</i> , 2017 , 9, 440	5.3	42
763	Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. <i>Movement Disorders</i> , 2017 , 32, 1264-1310	7	375
762	Deconstructing normal pressure hydrocephalus: Ventriculomegaly as early sign of neurodegeneration. <i>Annals of Neurology</i> , 2017 , 82, 503-513	9.4	95
761	Alcohol improves cerebellar learning deficit in myoclonus-dystonia: A clinical and electrophysiological investigation. <i>Annals of Neurology</i> , 2017 , 82, 543-553	9.4	26
760	Progressive ataxia and palatal tremor: Two autopsy cases of a novel tauopathy. <i>Movement Disorders</i> , 2017 , 32, 1465-1473	7	13
759	Recurrent Impulse Control Disorder Associated with Rasagiline Treatment of Parkinson's Disease. <i>Canadian Journal of Neurological Sciences</i> , 2017 , 44, 447-448	1	3
758	Is there even such a thing as "idiopathic normal pressure hydrocephalus"?. <i>Annals of Neurology</i> , 2017 , 82, 1032	9.4	2
757	A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY-PD III). <i>Annals of Clinical and Translational Neurology</i> , 2017 , 4, 360-368	5.3	46
756	Will New Genetic Techniques Like Exome Sequencing Obviate the Need for Clinical Expertise? No. <i>Movement Disorders Clinical Practice</i> , 2017 , 4, 39-41	2.2	3
755	Fatigue in Parkinson's disease: The contribution of cerebral metabolic changes. <i>Human Brain Mapping</i> , 2017 , 38, 283-292	5.9	21

754	Motor Phenotype in Neurodegenerative Disorders: Gait and Balance Platform Study Design Protocol for the Ontario Neurodegenerative Research Initiative (ONDRI). <i>Journal of Alzheimer's Disease</i> , 2017 , 59, 707-721	4.3	40
753	Whole-genome sequencing suggests mechanisms for 22q11.2 deletion-associated Parkinson's disease. <i>PLoS ONE</i> , 2017 , 12, e0173944	3.7	11
752	A Bayesian mathematical model of motor and cognitive outcomes in Parkinson's disease. <i>PLoS ONE</i> , 2017 , 12, e0178982	3.7	5
751	Asymmetric neuromodulation of motor circuits in Parkinson's disease: The role of subthalamic deep brain stimulation. <i>Surgical Neurology International</i> , 2017 , 8, 261	1	13
750	MRI signs of multiple system atrophy preceding the clinical diagnosis: the case for an imaging-supported probable MSA diagnostic category. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 443-4	5.5	18
749	The long-term outcome of orthostatic tremor. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 167-72	5.5	29
748	Reply letter to Jinnah "Locus pocus" and Albanese "Complex dystonia is not a category in the new 2013 consensus classification": Necessary evolution, no magic!. <i>Movement Disorders</i> , 2016 , 31, 1760-1762	7	1
747	Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's. <i>Annals of Neurology</i> , 2016 , 80, 674-685	9.4	154
746	Neurologic diagnostic criteria for functional neurologic disorders. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2016 , 139, 193-212	3	14
745	Unusual tremor syndromes: know in order to recognise. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 1191-1203	5.5	35
744	Fatigue in Parkinson's disease: report from a multidisciplinary symposium. <i>Npj Parkinson's Disease</i> , 2016 , 2,	9.7	45
743	α-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era. <i>Trends in Neurosciences</i> , 2016 , 39, 750-762	13.3	92
742	Learning More from Finger Tapping in Parkinson's Disease: Up and Down from Dyskinesia to Bradykinesia. <i>Movement Disorders Clinical Practice</i> , 2016 , 3, 184-187	2.2	5
741	Parkinson disease in 2015: Evolving basic, pathological and clinical concepts in PD. <i>Nature Reviews Neurology</i> , 2016 , 12, 65-6	15	113
740	Cortical Plasticity Induction by Pairing Subthalamic Nucleus Deep-Brain Stimulation and Primary Motor Cortical Transcranial Magnetic Stimulation in Parkinson's Disease. <i>Journal of Neuroscience</i> , 2016 , 36, 396-404	6.6	47
739	Mutation analysis of CHCHD2 in Canadian patients with familial Parkinson's disease. <i>Neurobiology of Aging</i> , 2016 , 38, 217.e7-217.e8	5.6	15
738	Orthostatic hypotension, cerebral hypoperfusion, and visuospatial deficits in Lewy body disorders. <i>Parkinsonism and Related Disorders</i> , 2016 , 22, 80-6	3.6	24
737	The role of mutations in COL6A3 in isolated dystonia. <i>Journal of Neurology</i> , 2016 , 263, 730-4	5.5	11

736	Progression of neuropsychiatric and cognitive features due to exons 2 to 5 deletion in the epsilon-sarcoglycan gene: a case report. <i>Neurocase</i> , 2016 , 22, 215-9	0.8	4
735	Development and validation of a carers quality-of-life questionnaire for parkinsonism (PQoL Carers). <i>Quality of Life Research</i> , 2016 , 25, 81-8	3.7	14
734	Characterization of Movement Disorder Phenomenology in Genetically Proven, Familial Frontotemporal Lobar Degeneration: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2016 , 11, e0153852	3.7	17
733	Disrupted Nodal and Hub Organization Account for Brain Network Abnormalities in Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2016 , 8, 259	5.3	35
732	Deficits in the Mimicry of Facial Expressions in Parkinson's Disease. <i>Frontiers in Psychology</i> , 2016 , 7, 780	3.4	30
731	Neurogenic orthostatic hypotension and supine hypertension in Parkinson's disease and related synucleinopathies: prioritisation of treatment targets. <i>Lancet Neurology</i> , 2016 , 15, 954-966	24.1	78
730	Technology in Parkinson's disease: Challenges and opportunities. <i>Movement Disorders</i> , 2016 , 31, 1272-82	7	305
729	A novel KCNA1 mutation in a family with episodic ataxia and malignant hyperthermia. <i>Neurogenetics</i> , 2016 , 17, 245-249	3	17
728	Parkinson's disease-related fatigue: A case definition and recommendations for clinical research. <i>Movement Disorders</i> , 2016 , 31, 625-31	7	63
727	Clozapine in Parkinsonian Rest Tremor: A Review of Outcomes, Adverse Reactions, and Possible Mechanisms of Action. <i>Movement Disorders Clinical Practice</i> , 2016 , 3, 116-124	2.2	13
726	Focal Predominant Forms of Posthypoxic Action Myoclonus. <i>Movement Disorders Clinical Practice</i> , 2016 , 3, 417-420	2.2	1
725	Paroxysmal Hemiballism/Hemichorea Resulting from Transient Ischemic Attacks. <i>Movement Disorders Clinical Practice</i> , 2016 , 3, 303-305	2.2	5
724	Augmented Restless Legs Syndrome with Marked Hyperkinesias and Impulsive-Compulsive Behaviors. <i>Movement Disorders Clinical Practice</i> , 2016 , 3, 412-414	2.2	
723	Nomenclature of genetic movement disorders: Recommendations of the international Parkinson and movement disorder society task force. <i>Movement Disorders</i> , 2016 , 31, 436-57	7	148
722	Contribution of insula in Parkinson's disease: A quantitative meta-analysis study. <i>Human Brain Mapping</i> , 2016 , 37, 1375-92	5.9	30
721	Factors influencing the outcome of deep brain stimulation: Placebo, nocebo, lessebo, and lesion effects. <i>Movement Disorders</i> , 2016 , 31, 290-6	7	54
720	Appendectomy in mid and later life and risk of Parkinson's disease: A population-based study. <i>Movement Disorders</i> , 2016 , 31, 1243-7	7	38
719	'Under pressure': is there a link between orthostatic hypotension and cognitive impairment in Synucleinopathies?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 1311-1321	5.5	49

718	Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study. <i>Brain</i> , 2016 , 139, 2050-62	11.2	38
717	The new definition and diagnostic criteria of Parkinson's disease. <i>Lancet Neurology, The</i> , 2016 , 15, 546-8	24.1	61
716	Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials. <i>Parkinsonism and Related Disorders</i> , 2016 , 28, 41-48	3.6	23
715	Deep Brain Stimulation in Rare Inherited Dystonias. <i>Brain Stimulation</i> , 2016 , 9, 905-910	5.1	20
714	Abolishing the 1-year rule: How much evidence will be enough?. <i>Movement Disorders</i> , 2016 , 31, 1623-1627		35
713	A case cluster of variant Creutzfeldt-Jakob disease linked to the Kingdom of Saudi Arabia. <i>Brain</i> , 2016 , 139, 2609-2616	11.2	8
712	Early Clinical Predictors of Treatment-Resistant and Functional Outcomes in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2016 , 3, 53-58	2.2	1
711	Integrated safety of levodopa-carbidopa intestinal gel from prospective clinical trials. <i>Movement Disorders</i> , 2016 , 31, 538-46	7	65
710	Long-term double-blinded unilateral pedunculopontine area stimulation in Parkinson's disease. <i>Movement Disorders</i> , 2016 , 31, 1570-1574	7	44
709	Practical guidelines for managing adults with 22q11.2 deletion syndrome. <i>Genetics in Medicine</i> , 2015 , 17, 599-609	8.1	154
708	Effects of subthalamic nucleus stimulation on motor cortex plasticity in Parkinson disease. <i>Neurology</i> , 2015 , 85, 425-32	6.5	34
707	Dopamine agonist withdrawal syndrome (DAWS) symptoms in Parkinson's disease patients treated with levodopa-carbidopa intestinal gel infusion. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 968-71	3.6	21
706	Repetitive transcranial magnetic stimulation plus standardized suggestion of benefit for functional movement disorders: an open label case series. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 407-12	3.6	17
705	Phenotype-specific diagnosis of functional (psychogenic) movement disorders. <i>Current Neurology and Neuroscience Reports</i> , 2015 , 15, 32	6.6	78
704	Plasma near-infrared spectroscopy for diagnosis of idiopathic Parkinson's disease: the SPIN-PD study. <i>Biomarkers in Medicine</i> , 2015 , 9, 89-97	2.3	4
703	Parkinson's disease. <i>Lancet, The</i> , 2015 , 386, 896-912	40	2652
702	Gastrointestinal dysfunction in Parkinson's disease. <i>Lancet Neurology, The</i> , 2015 , 14, 625-39	24.1	436
701	Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export. <i>Nature Genetics</i> , 2015 , 47, 579-81	36.3	176

700	Response to clozapine in a clinically identifiable subtype of schizophrenia. <i>British Journal of Psychiatry</i> , 2015 , 206, 484-91	5.4	44
699	Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results. <i>Movement Disorders</i> , 2015 , 30, 500-9	7	151
698	Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with α -synucleinopathies. <i>Neurobiology of Disease</i> , 2015 , 78, 162-71	7.5	58
697	Effects of rasagiline on the progression of nonmotor scores of the MDS-UPDRS. <i>Movement Disorders</i> , 2015 , 30, 589-92	7	19
696	Restless genital syndrome--in reply. <i>JAMA Neurology</i> , 2015 , 72, 479-80	17.2	
695	Mutation analysis of CHCHD10 in different neurodegenerative diseases. <i>Brain</i> , 2015 , 138, e380	11.2	67
694	Large-scale assessment of polyglutamine repeat expansions in Parkinson disease. <i>Neurology</i> , 2015 , 85, 1283-92	6.5	20
693	On the long-term outcome of orthostatic tremor. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 1290-1	3.6	2
692	Behavioral effects of levodopa. <i>Movement Disorders</i> , 2015 , 30, 90-102	7	52
691	Mutation analysis of patients with neurodegenerative disorders using NeuroX array. <i>Neurobiology of Aging</i> , 2015 , 36, 545.e9-14	5.6	24
690	Salience network and parahippocampal dopamine dysfunction in memory-impaired Parkinson disease. <i>Annals of Neurology</i> , 2015 , 77, 269-80	9.4	62
689	Investing in the future: stimulation of the medial prefrontal cortex reduces discounting of delayed rewards. <i>Neuropsychopharmacology</i> , 2015 , 40, 546-53	8.7	69
688	Imaging changes associated with cognitive abnormalities in Parkinson's disease. <i>Brain Structure and Function</i> , 2015 , 220, 2249-61	4	35
687	Disease-modifying strategies for Parkinson's disease. <i>Movement Disorders</i> , 2015 , 30, 1442-50	7	146
686	MDS research criteria for prodromal Parkinson's disease. <i>Movement Disorders</i> , 2015 , 30, 1600-11	7	645
685	Protocol of a randomised delayed-start double-blind placebo-controlled multi-centre trial for Levodopa in EARly Parkinson's disease: the LEAP-study. <i>BMC Neurology</i> , 2015 , 15, 236	3.1	10
684	Dystonic Pseudo Foot Drop. <i>Movement Disorders Clinical Practice</i> , 2015 , 2, 295-298	2.2	3
683	Successful treatment of functional palatal tremor: Insights into pathogenesis and management. <i>Movement Disorders</i> , 2015 , 30, 875-6	7	7

682	Movement disorders and other motor abnormalities in adults with 22q11.2 deletion syndrome. <i>American Journal of Medical Genetics, Part A</i> , 2015 , 167A, 639-45	2.5	43
681	Genome-wide variant by serum urate interaction in Parkinson's disease. <i>Annals of Neurology</i> , 2015 , 78, 731-41	9.4	8
680	Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial. <i>Annals of Neurology</i> , 2015 , 78, 248-57	9.4	190
679	Similar striatal D2/D3 dopamine receptor availability in adults with Tourette syndrome compared with healthy controls: A [(11) C]-(+)-PHNO and [(11) C]raclopride positron emission tomography imaging study. <i>Human Brain Mapping</i> , 2015 , 36, 2592-601	5.9	14
678	Vascular Parkinsonism: deconstructing a syndrome. <i>Movement Disorders</i> , 2015 , 30, 886-94	7	63
677	Minimal change multiple system atrophy: an aggressive variant?. <i>Movement Disorders</i> , 2015 , 30, 960-7	7	30
676	Imaging Striatal Microglial Activation in Patients with Parkinson's Disease. <i>PLoS ONE</i> , 2015 , 10, e0138723	3.7	67
675	Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease. <i>JAMA Neurology</i> , 2015 , 72, 100-5	17.2	191
674	Helicobacter pylori infection is associated with worse severity of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 221-5	3.6	78
673	Unfreezing of gait in patients with Parkinson's disease. <i>Lancet Neurology, The</i> , 2015 , 14, 675-7	24.1	16
672	Colonic mucosal a-synuclein lacks specificity as a biomarker for Parkinson disease. <i>Neurology</i> , 2015 , 84, 609-16	6.5	110
671	Deep brain stimulation for Parkinson disease in elderly individuals. <i>JAMA Neurology</i> , 2015 , 72, 367	17.2	3
670	MDS clinical diagnostic criteria for Parkinson's disease. <i>Movement Disorders</i> , 2015 , 30, 1591-601	7	2371
669	Author response. <i>Neurology</i> , 2015 , 85, 742-3	6.5	2
668	Rapid-Onset Dystonia-Parkinsonism in a Chinese Girl with a De Novo c.2267G>A (p.R756H) Genetic Mutation. <i>Movement Disorders Clinical Practice</i> , 2015 , 2, 74-75	2.2	4
667	Placebo effect of medication cost in Parkinson disease: a randomized double-blind study. <i>Neurology</i> , 2015 , 84, 794-802	6.5	87
666	In pursuit of prodromal Parkinson's disease. <i>Lancet Neurology, The</i> , 2015 , 14, 27-8	24.1	1
665	Management of impulse control disorders in Parkinson's disease: Controversies and future approaches. <i>Movement Disorders</i> , 2015 , 30, 150-9	7	71

664	Implications of nocturnal symptoms towards the early diagnosis of Parkinson's disease. <i>Journal of Neural Transmission</i> , 2014 , 121 Suppl 1, S49-57	4.3	18
663	Combined insular and striatal dopamine dysfunction are associated with executive deficits in Parkinson's disease with mild cognitive impairment. <i>Brain</i> , 2014 , 137, 565-75	11.2	98
662	Can Isolated Enlarged Virchow-Robin Spaces Influence the Clinical Manifestations of Parkinson's Disease?. <i>Movement Disorders Clinical Practice</i> , 2014 , 1, 67-69	2.2	13
661	Uncovering the role of the insula in non-motor symptoms of Parkinson's disease. <i>Brain</i> , 2014 , 137, 2143-54	11.2	106
660	Designing clinical trials for dystonia. <i>Neurotherapeutics</i> , 2014 , 11, 117-27	6.4	14
659	The treatment of dystonic tremor: a systematic review. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014 , 85, 759-69	5.5	76
658	Pathogenesis-targeted, disease-modifying therapies in Parkinson disease. <i>Neurotherapeutics</i> , 2014 , 11, 6-23	6.4	89
657	Neuropathological findings in chorea-acanthocytosis: new insights into mechanisms underlying parkinsonism and seizures. <i>Acta Neuropathologica</i> , 2014 , 127, 613-5	14.3	20
656	Initiating dopaminergic treatment in Parkinson's disease. <i>Lancet, The</i> , 2014 , 384, 1164-6	4.0	13
655	Longitudinal quantitative MRI in multiple system atrophy and progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 222-5	3.6	21
654	Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. <i>Movement Disorders</i> , 2014 , 29, 454-62	7	290
653	Bilateral pallidal stimulation for sargoglycan epsilon negative myoclonus. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 915-8	3.6	14
652	From psychogenic movement disorder to functional movement disorder: it's time to change the name. <i>Movement Disorders</i> , 2014 , 29, 849-52	7	101
651	Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. <i>Lancet Neurology, The</i> , 2014 , 13, 676-85	24.1	197
650	Tremor retraining as therapeutic strategy in psychogenic (functional) tremor. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 647-50	3.6	28
649	Restless genital syndrome in Parkinson disease. <i>JAMA Neurology</i> , 2014 , 71, 1559-61	17.2	30
648	Antecollis and levodopa-responsive parkinsonism are late features of Dravet syndrome. <i>Neurology</i> , 2014 , 82, 2250-1	6.5	44
647	Peroxisomal D-bifunctional protein deficiency: three adults diagnosed by whole-exome sequencing. <i>Neurology</i> , 2014 , 82, 963-8	6.5	53

646	Another face of placebo: the lessebo effect in Parkinson disease: meta-analyses. <i>Neurology</i> , 2014 , 82, 1402-9	6.5	32
645	Reply to: Gray et al. <i>Movement Disorders</i> , 2014 , 29, 1225-6	7	1
644	Longitudinal follow-up of SWEDD subjects in the PRECEPT Study. <i>Neurology</i> , 2014 , 82, 1791-7	6.5	108
643	'Don't delay, start today': delaying levodopa does not delay motor complications. <i>Brain</i> , 2014 , 137, 2628-30	10	22
642	Global investigation and meta-analysis of the C9orf72 (G4C2) _n repeat in Parkinson disease. <i>Neurology</i> , 2014 , 83, 1906-13	6.5	49
641	A practical approach to remote longitudinal follow-up of Parkinson's disease: the FOUND study. <i>Movement Disorders</i> , 2014 , 29, 743-9	7	11
640	Alimentary, my dear Watson? The challenges of enteric α -synuclein as a Parkinson's disease biomarker. <i>Movement Disorders</i> , 2014 , 29, 444-50	7	64
639	Tremor in Spinocerebellar Ataxia Type 12. <i>Movement Disorders Clinical Practice</i> , 2014 , 1, 76-78	2.2	5
638	Subthalamic nucleus-deep brain stimulation for early motor complications in Parkinson's disease-the EARLYSTIM trial: early is not always better. <i>Movement Disorders</i> , 2014 , 29, 1751-6	7	56
637	Reply: dystonia after severe head injuries. <i>Movement Disorders</i> , 2014 , 29, 578-9	7	0
636	Functional/psychogenic movement disorders: do we know what they are?. <i>Movement Disorders</i> , 2014 , 29, 1696-7; discussion 1699-701	7	12
635	Michael J. Fox Foundation LRRK2 Consortium: geographical differences in returning genetic research data to study participants. <i>Genetics in Medicine</i> , 2014 , 16, 644-5	8.1	7
634	Differentiating between visual hallucination-free dementia with Lewy bodies and corticobasal syndrome on the basis of neuropsychology and perfusion single-photon emission computed tomography. <i>Alzheimer's Research and Therapy</i> , 2014 , 6, 71	9	12
633	Pharmacological treatment of Parkinson disease: a review. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 311, 1670-83	27.4	816
632	Tardive dyskinesia syndromes: current concepts. <i>Parkinsonism and Related Disorders</i> , 2014 , 20 Suppl 1, S113-7	3.6	69
631	Dopamine-agonists and impulsivity in Parkinson's disease: impulsive choices vs. impulsive actions. <i>Human Brain Mapping</i> , 2014 , 35, 2499-506	5.9	59
630	Prefrontal dopaminergic receptor abnormalities and executive functions in Parkinson's disease. <i>Human Brain Mapping</i> , 2013 , 34, 1591-604	5.9	47
629	The prion hypothesis in Parkinson's disease: Braak to the future. <i>Acta Neuropathologica Communications</i> , 2013 , 1, 2	7.3	155

628	Clinicopathological review of pallidonigrolyusian atrophy. <i>Movement Disorders</i> , 2013 , 28, 274-81	7	12
627	Movement disorder society unified Parkinson disease rating scale experiences in daily living: longitudinal changes and correlation with other assessments. <i>Movement Disorders</i> , 2013 , 28, 1980-6	7	31
626	AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. <i>Movement Disorders</i> , 2013 , 28, 1838-46	7	107
625	Commentary. <i>Movement Disorders</i> , 2013 , 28, 1806-7	7	1
624	Mutations in SLC20A2 are a major cause of familial idiopathic basal ganglia calcification. <i>Neurogenetics</i> , 2013 , 14, 11-22	3	111
623	HemiballismHemichorea 2013 , 151-161		2
622	βSynuclein oligomers and clinical implications for Parkinson disease. <i>Annals of Neurology</i> , 2013 , 73, 155-69.4	6.4	209
621	Efficacy and safety of T2000 in older patients with essential tremor. <i>Parkinsonism and Related Disorders</i> , 2013 , 19, 485-6	3.6	3
620	The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2013 , 43, 151-65.5	5.5	11
619	Timing of deep brain stimulation in Parkinson disease: a need for reappraisal?. <i>Annals of Neurology</i> , 2013 , 73, 565-75	9.4	53
618	Criteria for the diagnosis of corticobasal degeneration. <i>Neurology</i> , 2013 , 80, 496-503	6.5	1004
617	Caffeine consumption and risk of dyskinesia in CALM-PD. <i>Movement Disorders</i> , 2013 , 28, 380-3	7	41
616	Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. <i>Lancet Neurology</i> , 2013 , 12, 514-24	24.1	108
615	Whispering dysphonia (DYT4 dystonia) is caused by a mutation in the TUBB4 gene. <i>Annals of Neurology</i> , 2013 , 73, 537-45	9.4	98
614	Phenomenology and classification of dystonia: a consensus update. <i>Movement Disorders</i> , 2013 , 28, 863-73	7.3	1217
613	Trial designs used to study neuroprotective therapy in Parkinson's disease. <i>Movement Disorders</i> , 2013 , 28, 86-95	7	45
612	Parkinson's disease subtypes: lost in translation?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013 , 84, 409-15	5.5	138
611	Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013 , 84, 130-5	5.5	86

610	Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. <i>Neurology</i> , 2013 , 80, 1698-701	6.5	152
609	Mutations in GNAL cause primary torsion dystonia. <i>Nature Genetics</i> , 2013 , 45, 88-92	36.3	229
608	Voxel-based imaging of translocator protein 18 kDa (TSPO) in high-resolution PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013 , 33, 348-50	7.3	9
607	Extensive intracranial calcifications in a patient with a novel polymerase β 1 mutation. <i>Neurology</i> , 2013 , 81, 197-8	6.5	11
606	Association between early-onset Parkinson disease and 22q11.2 deletion syndrome: identification of a novel genetic form of Parkinson disease and its clinical implications. <i>JAMA Neurology</i> , 2013 , 70, 1359-66	17.2	107
605	Long-term subthalamic nucleus stimulation improves sensorimotor integration and proprioception. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013 , 84, 1020-8	5.5	32
604	Impact of mild cognitive impairment on health-related quality of life in Parkinson's disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2013 , 36, 67-75	2.6	36
603	Reply to Drs. Kurlan, Fasano, and Evans: A clinically useful definition of stereotypies. <i>Movement Disorders</i> , 2013 , 28, 405-6	7	
602	Hemichorea-hemiballism associated with hyperglycemia and a developmental venous anomaly. <i>Neurology</i> , 2013 , 81, 1181	6.5	1
601	The value of GRE, ADC and routine MRI in distinguishing Parkinsonian disorders. <i>Canadian Journal of Neurological Sciences</i> , 2013 , 40, 389-402	1	23
600	Reply to letter: Multiple system atrophy-parkinsonism with slow progression and prolonged survival: a diagnostic catch. <i>Movement Disorders</i> , 2013 , 28, 408	7	
599	Multiple impulse control disorders developing in Parkinson's disease after initiation of amantadine. <i>Movement Disorders</i> , 2012 , 27, 326	7	22
598	Perampanel, an AMPA antagonist, found to have no benefit in reducing "off" time in Parkinson's disease. <i>Movement Disorders</i> , 2012 , 27, 284-8	7	56
597	Stereotypies: a critical appraisal and suggestion of a clinically useful definition. <i>Movement Disorders</i> , 2012 , 27, 179-85	7	74
596	Acquired neurosyphilis presenting as movement disorders. <i>Movement Disorders</i> , 2012 , 27, 690-5	7	34
595	A case of neurosyphilis presenting with myoclonus, cerebellar ataxia, and speech disturbance. <i>Movement Disorders</i> , 2012 , 27, 794	7	10
594	Stem cell therapy for Parkinson's disease. <i>Annals of Neurology</i> , 2012 , 71, 283; author reply 284	9.4	4
593	Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations. <i>Lancet Neurology</i> , 2012 , 11, 643-50	24.1	37

592	Psychogenic facial movement disorders: clinical features and associated conditions. <i>Movement Disorders</i> , 2012 , 27, 1544-51	7	73
591	Palliative care for advanced Parkinson disease: an interdisciplinary clinic and new scale, the ESAS-PD. <i>Parkinsonism and Related Disorders</i> , 2012 , 18 Suppl 3, S6-9	3.6	74
590	A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants. <i>Journal of Medical Genetics</i> , 2012 , 49, 721-6	5.8	78
589	Multiple sclerosis and extract of cannabis: results of the MUSEC trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012 , 83, 1125-32	5.5	142
588	Pardoprinox as adjunct therapy to levodopa in patients with Parkinson's disease experiencing motor fluctuations: results of a double-blind, randomized, placebo-controlled, trial. <i>Parkinsonism and Related Disorders</i> , 2012 , 18, 370-6	3.6	28
587	Associated movement disorders in orthostatic tremor. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012 , 83, 725-9	5.5	36
586	Large-scale replication and heterogeneity in Parkinson disease genetic loci. <i>Neurology</i> , 2012 , 79, 659-67	6.5	106
585	Caffeine for treatment of Parkinson disease: a randomized controlled trial. <i>Neurology</i> , 2012 , 79, 651-8	6.5	197
584	Investigation of c9orf72 in 4 neurodegenerative disorders. <i>Archives of Neurology</i> , 2012 , 69, 1583-90		83
583	Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. <i>Movement Disorders</i> , 2012 , 27, 1392-7	7	94
582	Reconciling Braak's model of Parkinson's disease with a prion-like spread of alpha synuclein pathology. <i>Basal Ganglia</i> , 2012 , 2, 167-170		2
581	Movement disorders in patients with diabetes mellitus. <i>Journal of the Neurological Sciences</i> , 2012 , 314, 5-11	3.2	28
580	Extrastriatal dopaminergic abnormalities of DA homeostasis in Parkinson's patients with medication-induced pathological gambling: a [¹¹ C] FLB-457 and PET study. <i>Neurobiology of Disease</i> , 2012 , 48, 519-25	7.5	101
579	Wilson disease: Canadian perspectives on presentation and outcomes from an adult ambulatory setting. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2012 , 26, 333-9		12
578	How does parkinsonism start? Prodromal parkinsonism motor changes in idiopathic REM sleep behaviour disorder. <i>Brain</i> , 2012 , 135, 1860-70	11.2	207
577	Toward a redefinition of Parkinson's disease. <i>Movement Disorders</i> , 2012 , 27, 54-60	7	132
576	Premotor Parkinson's disease: concepts and definitions. <i>Movement Disorders</i> , 2012 , 27, 608-16	7	108
575	Extreme task specificity: is it dystonia or another form of motor programming abnormality?. <i>Movement Disorders</i> , 2012 , 27, 1202-3	7	0

574	Multiple system atrophy-parkinsonism with slow progression and prolonged survival: a diagnostic catch. <i>Movement Disorders</i> , 2012 , 27, 1186-90	7	72
573	The pill questionnaire in a nondemented Parkinson's disease population. <i>Movement Disorders</i> , 2012 , 27, 1308-11	7	14
572	Fixing the broken system of genetic locus symbols: Parkinson disease and dystonia as examples. <i>Neurology</i> , 2012 , 78, 1016-24	6.5	51
571	Hemichorea-hemiballism associated with hyperglycemia and a developmental venous anomaly. <i>Neurology</i> , 2012 , 78, 838-9	6.5	5
570	Parkinsonism 2012 , 2326-2333		
569	Other Movement Disorders 2012 , 2333-2342		
568	Psychogenic dystonia 2012 , 307-319		
567	Cannabinoid, CB1 agonists in cervical dystonia: Failure in a phase IIa randomized controlled trial. <i>Basal Ganglia</i> , 2011 , 1, 91-95		26
566	Non-Dopaminergic Approaches to the Treatment of Parkinson's Disease 2011 , 432-454		
565	Overview of the Medical Treatment of the Non-Motor and Non-Dopaminergic Features of Parkinson's Disease 2011 , 394-408		
564	Dopamine Dysregulation Syndrome 2011 , 202-214		1
563	Sleep Disorders in Parkinson's Disease 2011 , 233-239		
562	Psychosis in Parkinson's Disease 2011 , 170-182		
561	Depression in Parkinson's Disease 2011 , 183-192		
560	Clinical Features of Dementia Associated with Parkinson's Disease and Dementia with Lewy Bodies 2011 , 134-144		1
559	Anxiety Syndromes and Panic Attacks 2011 , 193-201		1
558	Neuronal Mechanisms of REM Sleep and their Role in REM Sleep Behavior Disorder 2011 , 240-245		1
557	Neurobiology of Impulse Control Disorders in Parkinson's Disease 2011 , 215-232		

556 Orthopedic Complications of Parkinson's Disease **2011**, 374-386

555	Role of sepiapterin reductase gene at the PARK3 locus in Parkinson's disease. <i>Neurobiology of Aging</i> , 2011 , 32, 2108.e1-5	5.6	15
554	Development of a non-motor fluctuation assessment instrument for Parkinson disease. <i>Parkinson's Disease</i> , 2011 , 2011, 292719	2.6	21
553	Speech and Voice Disorders in Parkinson's Disease 2011 , 346-360		6
552	Translational research in neurology and neuroscience 2011: movement disorders. <i>Archives of Neurology</i> , 2011 , 68, 709-16		7
551	A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. <i>Lancet Neurology</i> , 2011 , 10, 415-23	24.1	159
550	The Emerging Entity of Pre-Motor Parkinson's Disease 2011 , 93-104		1
549	Functional Imaging Studies in Parkinson's Disease: The Non-Dopaminergic Systems 2011 , 105-110		
548	Other Non-Motor Symptoms of Parkinson's Disease 2011 , 387-393		
547	Pain and Paresthesia in Parkinson's Disease 2011 , 315-332		2
546	Deep brain stimulation for dystonia. <i>Movement Disorders</i> , 2011 , 26 Suppl 1, S3-4	7	2
545	Thalamic neuronal and EMG activity in psychogenic dystonia compared with organic dystonia. <i>Movement Disorders</i> , 2011 , 26, 1348-52	7	16
544	Psychogenic movement disorders: past developments, current status, and future directions. <i>Movement Disorders</i> , 2011 , 26, 1175-86	7	38
543	Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts. <i>Movement Disorders</i> , 2011 , 26, 608-13	7	16
542	Pardoprinox in early Parkinson's disease: results from 2 large, randomized double-blind trials. <i>Movement Disorders</i> , 2011 , 26, 1464-76	7	32
541	A critical appraisal of the premotor symptoms of Parkinson's disease: potential usefulness in early diagnosis and design of neuroprotective trials. <i>Movement Disorders</i> , 2011 , 26, 775-83	7	101
540	Tongue control for swallowing in Parkinson's disease: effects of age, rate, and stimulus consistency. <i>Movement Disorders</i> , 2011 , 26, 1725-9	7	19
539	Expanding the phenomenology of benign hereditary chorea: evolution from chorea to myoclonus and dystonia. <i>Movement Disorders</i> , 2011 , 26, 2296-7	7	12

538	Early-onset tardive dyskinesia in a neuroleptic-naive patient exposed to low-dose quetiapine. <i>Movement Disorders</i> , 2011 , 26, 2297-8	7	5
537	The curious case of phenocopies in families with genetic Parkinson's disease. <i>Movement Disorders</i> , 2011 , 26, 1793-802	7	34
536	Caffeine in Parkinson's disease: a pilot open-label, dose-escalation study. <i>Movement Disorders</i> , 2011 , 26, 2427-31	7	32
535	Impulse control disorders in Parkinson disease: a multicenter case-control study. <i>Annals of Neurology</i> , 2011 , 69, 986-96	9.4	296
534	Movement disorders on YouTube--caveat spectator. <i>New England Journal of Medicine</i> , 2011 , 365, 1160-159.2		59
533	Potential placebo effect in assessing idiopathic normal pressure hydrocephalus. <i>Journal of Neurosurgery</i> , 2011 , 114, 1428-31	3.2	16
532	Ten-year outcome of subthalamic stimulation in Parkinson disease: a blinded evaluation. <i>Archives of Neurology</i> , 2011 , 68, 1550-6		304
531	Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers. <i>Neurology</i> , 2011 , 77, 325-33	6.5	126
530	Unilateral subdural motor cortex stimulation improves essential tremor but not Parkinson's disease. <i>Brain</i> , 2011 , 134, 2096-105	11.2	73
529	The psychogenic toe signs. <i>Neurology</i> , 2011 , 77, 508-9	6.5	15
528	Surgical correction of kyphosis in patients with camptocormia due to Parkinson's disease: a retrospective evaluation. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011 , 82, 364-8	5.5	33
527	Comprehensive mutational analysis of LRRK2 reveals variants supporting association with autosomal dominant Parkinson's disease. <i>Journal of Human Genetics</i> , 2011 , 56, 671-5	4.3	9
526	Clinical vignettes in Parkinson's disease: a collection of unusual medication-induced hallucinations, delusions, and compulsive behaviours. <i>International Journal of Neuroscience</i> , 2011 , 121, 472-6	2	5
525	Clinical trials of disease-modifying therapies for neurodegenerative diseases: the challenges and the future. <i>Nature Medicine</i> , 2010 , 16, 1223-6	50.5	63
524	The nature and time course of cortical activation following subthalamic stimulation in Parkinson's disease. <i>Cerebral Cortex</i> , 2010 , 20, 1926-36	5.1	100
523	Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. <i>Archives of Neurology</i> , 2010 , 67, 589-95		988
522	Therapy of the Motor Features of Parkinson's Disease. <i>Blue Books of Neurology</i> , 2010 , 34, 252-272		
521	Patient perception of dyskinesia in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010 , 81, 1112-5	5.5	38

520	Drug-induced deactivation of inhibitory networks predicts pathological gambling in PD. <i>Neurology</i> , 2010 , 75, 1711-6	6.5	171
519	Oxidative stress alters the regulatory control of p66Shc and Akt in PINK1 deficient cells. <i>Biochemical and Biophysical Research Communications</i> , 2010 , 399, 331-5	3.4	18
518	LRRK2 and Parkin mutations in a family with parkinsonism-Lack of genotype-phenotype correlation. <i>Neurobiology of Aging</i> , 2010 , 31, 721-2	5.6	6
517	A survey on the impact of the menstrual cycle on movement disorders severity. <i>Canadian Journal of Neurological Sciences</i> , 2010 , 37, 478-81	1	5
516	Event-related desynchronization of motor cortical oscillations in patients with multiple system atrophy. <i>Experimental Brain Research</i> , 2010 , 206, 1-13	2.3	8
515	Extrastriatal dopaminergic dysfunction in tourette syndrome. <i>Annals of Neurology</i> , 2010 , 67, 170-81	9.4	84
514	Dystonia in complex regional pain syndrome type I. <i>Annals of Neurology</i> , 2010 , 67, 412-4	9.4	21
513	Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. <i>Annals of Neurology</i> , 2010 , 68, 18-27	9.4	270
512	Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. <i>Annals of Neurology</i> , 2010 , 68, 963-8	9.4	105
511	Involvement of the cerebellothalamocortical pathway in Parkinson disease. <i>Annals of Neurology</i> , 2010 , 68, 816-24	9.4	90
510	Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. <i>Movement Disorders</i> , 2010 , 25, 578-86	7	319
509	The nonmotor symptoms of Parkinson's disease--an overview. <i>Movement Disorders</i> , 2010 , 25 Suppl 1, S123-30	7	103
508	A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy. <i>Movement Disorders</i> , 2010 , 25, 1077-81	7	90
507	Neuronal intranuclear inclusion disease: two cases of dopa-responsive juvenile parkinsonism with drug-induced dyskinesia. <i>Movement Disorders</i> , 2010 , 25, 1274-9	7	17
506	Effect of movement frequency on repetitive finger movements in patients with Parkinson's disease. <i>Movement Disorders</i> , 2010 , 25, 252; author reply 253	7	3
505	Double-blind study of pramipexole, a new partial dopamine agonist, in early Parkinson's disease. <i>Movement Disorders</i> , 2010 , 25, 738-46	7	27
504	Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease. <i>Movement Disorders</i> , 2010 , 25, 1801-8	7	16
503	Reply: Based on the available randomized trial patients should say no to glutathione for Parkinson's disease. <i>Movement Disorders</i> , 2010 , 25, 961-2; author reply 962-3	7	8

502	Characteristic head drops and axial extension in advanced chorea-acanthocytosis. <i>Movement Disorders</i> , 2010 , 25, 1487-91	7	42
501	The grasp reflex: a symptom in need of treatment. <i>Movement Disorders</i> , 2010 , 25, 2479-85	7	6
500	Definition and classification of hyperkinetic movements in childhood. <i>Movement Disorders</i> , 2010 , 25, 1538-49	7	275
499	Drug-induced cranial myoclonus. <i>Movement Disorders</i> , 2010 , 25, 2264-5	7	11
498	Standard guidelines for publication of deep brain stimulation studies in Parkinson's disease (Guide4DBS-PD). <i>Movement Disorders</i> , 2010 , 25, 1530-7	7	17
497	Long-term effect of unilateral pallidotomy on levodopa-induced dyskinesia. <i>Movement Disorders</i> , 2010 , 25, 1496-8	7	16
496	Impaired presynaptic inhibition in the motor cortex in Parkinson disease. <i>Neurology</i> , 2009 , 72, 842-9	6.5	56
495	Urate as a predictor of the rate of clinical decline in Parkinson disease. <i>Archives of Neurology</i> , 2009 , 66, 1460-8		265
494	When and how should treatment be started in Parkinson disease?. <i>Neurology</i> , 2009 , 72, S39-43	6.5	46
493	A new sensitive imaging biomarker for Parkinson disease?. <i>Neurology</i> , 2009 , 72, 1374-5	6.5	15
492	Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. <i>Brain</i> , 2009 , 132, 1376-85	11.2	432
491	Reply: Parkinson's disease, DBS and suicide: a role for serotonin?. <i>Brain</i> , 2009 , 132, e127-e127	11.2	4
490	Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a trigger for pathological gambling in Parkinson's disease?. <i>Neuropsychopharmacology</i> , 2009 , 34, 2758-66	8.7	126
489	Overview of the extranigral aspects of Parkinson disease. <i>Archives of Neurology</i> , 2009 , 66, 167-72		128
488	Safety and tolerability of pardoprinox, a new partial dopamine agonist, in a randomized, controlled study of patients with advanced Parkinson's disease. <i>European Neurology</i> , 2009 , 62, 40-8	2.1	22
487	Selective enhancement of rapid eye movement sleep by deep brain stimulation of the human pons. <i>Annals of Neurology</i> , 2009 , 66, 110-4	9.4	91
486	Dopaminergic transplantation for Parkinson's disease: current status and future prospects. <i>Annals of Neurology</i> , 2009 , 66, 591-6	9.4	70
485	Stimulation of the subthalamic nucleus and impulsivity: release your horses. <i>Annals of Neurology</i> , 2009 , 66, 817-24	9.4	199

484	Cerebral blood flow changes induced by pedunculopontine nucleus stimulation in patients with advanced Parkinson's disease: a [(15)O] H ₂ O PET study. <i>Human Brain Mapping</i> , 2009 , 30, 3901-9	5.9	88
483	Impairments of speed and amplitude of movement in Parkinson's disease: a pilot study. <i>Movement Disorders</i> , 2009 , 24, 1001-8	7	71
482	Opinions and clinical practices related to diagnosing and managing patients with psychogenic movement disorders: An international survey of movement disorder society members. <i>Movement Disorders</i> , 2009 , 24, 1366-74	7	117
481	Alien hand syndrome and dystonia in a pediatric patient. <i>Movement Disorders</i> , 2009 , 24, 1557-9	7	6
480	Hereditary parkinsonism: Parkinson disease look-alikes--an algorithm for clinicians to "PARK" genes and beyond. <i>Movement Disorders</i> , 2009 , 24, 2042-58	7	49
479	A longitudinal program for biomarker development in Parkinson's disease: a feasibility study. <i>Movement Disorders</i> , 2009 , 24, 2081-90	7	44
478	ATP13A2 variants in early-onset Parkinson's disease patients and controls. <i>Movement Disorders</i> , 2009 , 24, 2104-11	7	54
477	Rasagiline-induced spontaneous ejaculation. <i>Movement Disorders</i> , 2009 , 24, 2160-1	7	5
476	A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts. <i>Movement Disorders</i> , 2009 , 24, 2370-8	7	10
475	Understanding disability in Tourette syndrome. <i>Developmental Medicine and Child Neurology</i> , 2009 , 51, 468-72	3.3	52
474	Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. <i>European Journal of Neurology</i> , 2009 , 16, 297-309	6	143
473	Myoclonus in complex regional pain syndrome. <i>Movement Disorders</i> , 2009 , 24, 314-6; author reply 316	7	18
472	Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. <i>New England Journal of Medicine</i> , 2009 , 361, 1651-61	59.2	1351
471	A double-blind, delayed-start trial of rasagiline in Parkinson's disease. <i>New England Journal of Medicine</i> , 2009 , 361, 1268-78	59.2	694
470	Prenatal and perinatal morbidity in children with Tourette syndrome and attention-deficit hyperactivity disorder. <i>Journal of Developmental and Behavioral Pediatrics</i> , 2009 , 30, 115-21	2.4	37
469	Psychogenic movement disorders. <i>Current Opinion in Neurology</i> , 2009 , 22, 430-6	7.1	205
468	Polymyoclonus, laryngospasm, and cerebellar ataxia associated with adenocarcinoma and multiple neural cation channel autoantibodies. <i>Archives of Neurology</i> , 2009 , 66, 1285-7		2
467	Dopamine Agonists Diminish Value Sensitivity of the Orbitofrontal Cortex: A Trigger for Pathological Gambling in Parkinson's Disease?. <i>Neuropsychopharmacology</i> , 2009 , 34, 2758-66	8.7	65

466 Surgery for Movement Disorders: An Overview **2009**, 1443-1466

465 Non-dopaminergic treatments in development for Parkinson's disease. *Lancet Neurology*, **2008**, 7, 927-38 24.1 92

464 A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. *Brain*, **2008**, 131, 2720-8 11.2 392

463 Bilateral subthalamic stimulation in Parkin and PINK1 parkinsonism. *Neurology*, **2008**, 70, 1186-91 6.5 51

462 Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. *Archives of Neurology*, **2008**, 65, 716-23 25.1

461 Invited article: changing concepts in Parkinson disease: moving beyond the decade of the brain. *Neurology*, **2008**, 70, 1996-2003 6.5 65

460 Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. *Neurology*, **2008**, 71, 462; author reply 462-3 6.5 27

459 Impact of standard of care for psychosis in Parkinson disease. *Journal of Neurology, Neurosurgery and Psychiatry*, **2008**, 79, 1413-5 5.5 16

458 Pergolide associated cardiac valvulopathy based on Ontario administrative data. *Canadian Journal of Neurological Sciences*, **2008**, 35, 173-8 1 8

457 Treatment of Motor Complications in Advanced Parkinson's Disease **2008**, 71-90

456 Reduced intracortical and interhemispheric inhibitions in corticobasal syndrome. *Journal of Clinical Neurophysiology*, **2008**, 25, 304-12 2.2 20

455 PATIENT MANAGEMENT PROBLEM. *CONTINUUM Lifelong Learning in Neurology*, **2008**, 14, 182-193 3

454 The spectrum of orolingual tremor--a proposed classification system. *Movement Disorders*, **2008**, 23, 159-67 7 34

453 Phenotypic spectrum and sex effects in eleven myoclonus-dystonia families with epsilon-sarcoglycan mutations. *Movement Disorders*, **2008**, 23, 588-92 7 54

452 The G2019S LRRK2 mutation in Brazilian patients with Parkinson's disease: phenotype in monozygotic twins. *Movement Disorders*, **2008**, 23, 290-4 7 14

451 A comparison of the mini mental state exam to the Montreal cognitive assessment in identifying cognitive deficits in Parkinson's disease. *Movement Disorders*, **2008**, 23, 297-9 7 221

450 Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial. *Movement Disorders*, **2008**, 23, 653-9; quiz 776 7 109

449 Large deletions account for an increasing number of mutations in SGCE. *Movement Disorders*, **2008**, 23, 456-60 7 25

448	Levodopa-related motor complications--phenomenology. <i>Movement Disorders</i> , 2008 , 23 Suppl 3, S509-14		71
447	Reply: The variability of levodopa response in Parkinson's disease: Is sensitization reversible?. <i>Movement Disorders</i> , 2008 , 23, 925-925	7	
446	rCBF changes associated with PPN stimulation in a patient with Parkinson's disease: a PET study. <i>Movement Disorders</i> , 2008 , 23, 1051-1054	7	48
445	Do dyskinesia and pain share common pathophysiological mechanisms in Parkinson's disease?. <i>Movement Disorders</i> , 2008 , 23, 1689-95	7	77
444	A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. <i>Movement Disorders</i> , 2008 , 23, 2194-201	7	138
443	Electrophysiological features of myoclonus-dystonia. <i>Movement Disorders</i> , 2008 , 23, 2055-61	7	34
442	Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. <i>Movement Disorders</i> , 2008 , 23, 2129-70	7	3156
441	Myoclonus-dystonia: significance of large SGCE deletions. <i>Human Mutation</i> , 2008 , 29, 331-2	4-7	112
440	Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. <i>Lancet Neurology</i> , 2008 , 7, 583-90	24-1	1075
439	Movement Disorders: Diagnosis and Assessment 2008 , 293-325		3
438	Motor and non-motor fluctuations. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2007 , 84, 157-84	3	4
437	Characterization of REM-sleep associated ponto-geniculo-occipital waves in the human pons. <i>Sleep</i> , 2007 , 30, 823-7	1-1	80
436	Antidepressants and psychosis in Parkinson disease: a case series. <i>International Journal of Geriatric Psychiatry</i> , 2007 , 22, 601-4	3-9	18
435	Antipsychotic use in older adults with Parkinson's disease. <i>Movement Disorders</i> , 2007 , 22, 319-23	7	23
434	Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. <i>Movement Disorders</i> , 2007 , 22, 41-7	7	802
433	Unilateral versus bilateral tasks in early asymmetric Parkinson's disease: differential effects on bradykinesia. <i>Movement Disorders</i> , 2007 , 22, 328-33	7	28
432	Is there seasonal variation in risk of Parkinson's disease?. <i>Movement Disorders</i> , 2007 , 22, 1097-101	7	10
431	Gait abnormalities in psychogenic movement disorders. <i>Movement Disorders</i> , 2007 , 22, 395-9	7	107

430	Punding prevalence in Parkinson's disease. <i>Movement Disorders</i> , 2007 , 22, 1179-81	7	102
429	Rapid and reliable detection of exon rearrangements in various movement disorders genes by multiplex ligation-dependent probe amplification. <i>Movement Disorders</i> , 2007 , 22, 1708-14	7	13
428	Interhemispheric and ipsilateral connections in Parkinson's disease: relation to mirror movements. <i>Movement Disorders</i> , 2007 , 22, 813-21	7	88
427	Refinement of the DYT15 locus in myoclonus dystonia. <i>Movement Disorders</i> , 2007 , 22, 888-92	7	38
426	Orthostatic tremor in progressive supranuclear palsy. <i>Movement Disorders</i> , 2007 , 22, 1192-4	7	14
425	Levodopa response in long-term bilateral subthalamic stimulation for Parkinson's disease. <i>Movement Disorders</i> , 2007 , 22, 990-7	7	87
424	Sustained relief of dystonia following cessation of deep brain stimulation. <i>Movement Disorders</i> , 2007 , 22, 1958-62	7	49
423	Benign hereditary chorea revisited: a journey to understanding. <i>Movement Disorders</i> , 2007 , 22, 2297-305; quiz 2452	7	43
422	Subdural motor cortex stimulation in Parkinson's disease does not modify movement-related rCBF pattern. <i>Movement Disorders</i> , 2007 , 22, 2113-6	7	30
421	Reversible dopamine agonist induced anterocollis in a multiple system atrophy patient. <i>Movement Disorders</i> , 2007 , 22, 2292-3	7	10
420	Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. <i>Movement Disorders</i> , 2007 , 22, 2409-17	7	174
419	GDNF in Parkinson's disease: the perils of post-hoc power. <i>Journal of Neuroscience Methods</i> , 2007 , 163, 193-6	3	11
418	Deciphering the role of heterozygous mutations in genes associated with parkinsonism. <i>Lancet Neurology</i> , 2007 , 6, 652-62	24.1	242
417	Diagnosing psychogenic movement disorders-which criteria should be used in clinical practice?. <i>Nature Clinical Practice Neurology</i> , 2007 , 3, 134-5		15
416	Fixed dystonia unresponsive to pallidal stimulation improved by motor cortex stimulation. <i>Neurology</i> , 2007 , 69, 1062-3; author reply 1063	6.5	5
415	Genotype-phenotype correlation of paroxysmal nonkinesigenic dyskinesia. <i>Neurology</i> , 2007 , 68, 1782-9	6.5	141
414	Long-term outcome of bilateral pallidal deep brain stimulation for primary cervical dystonia. <i>Neurology</i> , 2007 , 68, 457-9	6.5	187
413	Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. <i>Archives of Neurology</i> , 2007 , 64, 212-6		289

412	Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study. <i>Neurology</i> , 2007 , 68, 1440; author reply 1440-1	6.5	2
411	The progression of Parkinson disease: a hypothesis. <i>Neurology</i> , 2007 , 68, 948-52	6.5	96
410	Involvement of the basal ganglia and cerebellar motor pathways in the preparation of self-initiated and externally triggered movements in humans. <i>Journal of Neuroscience</i> , 2007 , 27, 6029-36	6.6	54
409	Isolated diaphragmatic tremor: is there a spectrum in "respiratory myoclonus"? <i>Neurology</i> , 2007 , 69, 689-92	6.5	23
408	Subthalamic nucleus stimulation modulates afferent inhibition in Parkinson disease. <i>Neurology</i> , 2007 , 68, 356-63	6.5	52
407	Manganese-induced Parkinsonism associated with methcathinone (Ephedrone) abuse. <i>Archives of Neurology</i> , 2007 , 64, 886-9		87
406	Low-frequency repetitive transcranial magnetic stimulation for treatment of levodopa-induced dyskinesias. <i>Neurology</i> , 2007 , 68, 704-5	6.5	52
405	Neuronal firing rates and patterns in the globus pallidus internus of patients with cervical dystonia differ from those with Parkinson's disease. <i>Journal of Neurophysiology</i> , 2007 , 98, 720-9	3.2	109
404	An update on movement disorders: exciting developments but new obstacles. <i>Current Opinion in Neurology</i> , 2007 , 20, 432-433	7.1	
403	The etiopathogenesis of Parkinson disease and suggestions for future research. Part I. <i>Journal of Neuropathology and Experimental Neurology</i> , 2007 , 66, 251-7	3.1	88
402	The etiopathogenesis of Parkinson disease and suggestions for future research. Part II. <i>Journal of Neuropathology and Experimental Neurology</i> , 2007 , 66, 329-36	3.1	38
401	Clinical practice regarding dopamine-agonist use and driving in Parkinson's disease. <i>Canadian Journal of Neurological Sciences</i> , 2007 , 34, 438-42	1	2
400	Changes in cortical and pallidal oscillatory activity during the execution of a sensory trick in patients with cervical dystonia. <i>Experimental Neurology</i> , 2007 , 204, 845-8	5.7	41
399	The many faces of corticobasal degeneration. <i>Parkinsonism and Related Disorders</i> , 2007 , 13 Suppl 3, S336-40	5.4	78
398	Contemporary assessment and pharmacotherapy of Tourette syndrome. <i>NeuroRx</i> , 2006 , 3, 192-206		237
397	GDNF in treatment of Parkinson's disease: response to editorial. <i>Lancet Neurology</i> , 2006 , 5, 200-2	24.1	29
396	Neuroprotection in Parkinson's disease: and now for something completely different?. <i>Lancet Neurology</i> , 2006 , 5, 990-1	24.1	19
395	Homozygous and heterozygous PINK1 mutations: considerations for diagnosis and care of Parkinson's disease patients. <i>Movement Disorders</i> , 2006 , 21, 875-9	7	23

394	Crossroads in GDNF therapy for Parkinson's disease. <i>Movement Disorders</i> , 2006 , 21, 136-41	7	145
393	Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure. <i>Movement Disorders</i> , 2006 , 21, 1578-94	7	91
392	Deep brain stimulation for Parkinson's disease. <i>Movement Disorders</i> , 2006 , 21 Suppl 14, S168-70	7	53
391	Deep brain stimulation: preoperative issues. <i>Movement Disorders</i> , 2006 , 21 Suppl 14, S171-96	7	208
390	Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. <i>Movement Disorders</i> , 2006 , 21 Suppl 14, S290-304	7	651
389	Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. <i>Movement Disorders</i> , 2006 , 21, 1844-50	7	116
388	Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. <i>Movement Disorders</i> , 2006 , 21, 1941-6	7	207
387	Rapidly progressive sporadic dentatorubral pallidoluysian atrophy with intracytoplasmic inclusions and no CAG repeat expansion. <i>Movement Disorders</i> , 2006 , 21, 2251-4	7	10
386	Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. <i>Annals of Neurology</i> , 2006 , 59, 459-66	9.4	785
385	Interface between tauopathies and synucleinopathies: a tale of two proteins. <i>Annals of Neurology</i> , 2006 , 59, 449-58	9.4	204
384	Cortical and spinal abnormalities in psychogenic dystonia. <i>Annals of Neurology</i> , 2006 , 59, 825-34	9.4	169
383	Subthalamic nucleus stimulation: improvements in outcome with reprogramming. <i>Archives of Neurology</i> , 2006 , 63, 1266-72		49
382	Childhood onset in familial prion disease with a novel mutation in the PRNP gene. <i>Archives of Neurology</i> , 2006 , 63, 1016-21		18
381	The 'essentials' of essential palatal tremor: a reappraisal of the nosology. <i>Brain</i> , 2006 , 129, 832-40	11.2	92
380	Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. <i>Neurology</i> , 2006 , 67, 1254-76.5		365
379	Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study. <i>Neurology</i> , 2006 , 66, 1941-3	6.5	52
378	A case of a psychogenic "jumpy stump". <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006 , 77, 1103.5		15
377	Mirror movements in Parkinson's disease: effect of dopaminergic drugs. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006 , 77, 1194-5	5.5	17

376	Beta oscillatory activity in the subthalamic nucleus and its relation to dopaminergic response in Parkinson's disease. <i>Journal of Neurophysiology</i> , 2006 , 96, 3248-56	3.2	413
375	Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias. <i>Brain</i> , 2006 , 129, 1059-69.2		250
374	Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. <i>Neurology</i> , 2006 , 66, 845-51	6.5	328
373	Criteria for deep-brain stimulation in Parkinson's disease: review and analysis. <i>Expert Review of Neurotherapeutics</i> , 2006 , 6, 1695-705	4.3	55
372	Cardiac valvulopathy associated with pergolide use. <i>Canadian Journal of Neurological Sciences</i> , 2006 , 33, 27-33	1	19
371	Prospective prevalence of pathologic gambling and medication association in Parkinson disease. <i>Neurology</i> , 2006 , 66, 1750-2	6.5	273
370	Contemporary assessment and pharmacotherapy of Tourette syndrome. <i>Neurotherapeutics</i> , 2006 , 3, 192-206	6.4	
369	Psychogenic Dystonia. <i>Medical Psychiatry</i> , 2006 , 277-288		
368	Subthalamic Nucleus Stimulation: Improvements in Outcome With Reprogramming. <i>Archives of Neurology</i> , 2006 , 63, 1266-1272		93
367	LRRK2 gene in Parkinson disease: mutation analysis and case control association study. <i>Neurology</i> , 2005 , 65, 696-700	6.5	145
366	Apraxia in movement disorders. <i>Brain</i> , 2005 , 128, 1480-97	11.2	201
365	Psychogenic movement disorders. <i>Current Opinion in Neurology</i> , 2005 , 18, 399-404	7.1	41
364	Progress in clinical neurosciences: a forum on the early management of Parkinson's disease. <i>Canadian Journal of Neurological Sciences</i> , 2005 , 32, 277-86	1	3
363	Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohort. <i>Neurology</i> , 2005 , 64, 87-93.5	3.5	114
362	Analysis of the glucocerebrosidase gene in Parkinson's disease. <i>Movement Disorders</i> , 2005 , 20, 367-70	7	93
361	Pallidal deep brain stimulation influences both reflexive and voluntary saccades in Huntington's disease. <i>Movement Disorders</i> , 2005 , 20, 371-7	7	23
360	Does severity of Parkinson's disease vary according to season?. <i>Movement Disorders</i> , 2005 , 20, 476-479	7	7
359	Treatment of progressive supranuclear palsy and corticobasal degeneration. <i>Movement Disorders</i> , 2005 , 20 Suppl 12, S83-91	7	44

358	Normalization of voice in spasmodic dysphonia during transient global amnesia. <i>Movement Disorders</i> , 2005 , 20, 1228-9	7	
357	Alterations of striatal neurons in benign hereditary chorea. <i>Movement Disorders</i> , 2005 , 20, 1353-7	7	54
356	Firing rates of pallidal neurons are similar in Huntington's and Parkinson's disease patients. <i>Experimental Brain Research</i> , 2005 , 166, 230-6	2.3	66
355	Identification of a VPS13A founder mutation in French Canadian families with chorea-acanthocytosis. <i>Neurogenetics</i> , 2005 , 6, 151-8	3	30
354	Selected genetically engineered models relevant to human neurodegenerative disease 2005 , 176-195		1
353	Structural and functional magnetic resonance imaging in neurodegenerative diseases 2005 , 253-289		1
352	Corticobasal degeneration 2005 , 682-696		
351	Neurophysiology of Parkinson's disease, levodopa-induced dyskinesias, dystonia, Huntington's disease and myoclonus 2005 , 227-250		
350	Current and potential treatments of Parkinson's disease 2005 , 612-622		
349	Multiple system atrophy 2005 , 623-662		2
348	Changes in cortical excitability with thalamic deep brain stimulation. <i>Neurology</i> , 2005 , 64, 1913-9	6.5	37
347	A writing device improves writing in primary writing tremor. <i>Neurology</i> , 2005 , 64, 1648-50	6.5	37
346	Psychiatric symptoms in patients with Parkinson disease presenting for deep brain stimulation surgery. <i>Journal of Neurosurgery</i> , 2005 , 103, 246-51	3.2	41
345	Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. <i>Brain</i> , 2005 , 128, 2240-9	11.2	837
344	Mirror movements in parkinsonism: evaluation of a new clinical sign. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005 , 76, 1355-8	5.5	72
343	Parkinsonian Tremor. <i>Neurological Disease and Therapy</i> , 2005 , 195-220		7
342	Antidepressant treatment outcomes of psychogenic movement disorder. <i>Journal of Clinical Psychiatry</i> , 2005 , 66, 1529-34	4.6	102
341	Neurodegenerative Diseases: Neurobiology, Pathogenesis and Therapeutics 2005 ,		12

340	Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. <i>Archives of Neurology</i> , 2004 , 61, 1044-53		356
339	The gene for paroxysmal non-kinesigenic dyskinesia encodes an enzyme in a stress response pathway. <i>Human Molecular Genetics</i> , 2004 , 13, 3161-70	5.6	164
338	Analysis of the PINK1 gene in a large cohort of cases with Parkinson disease. <i>Archives of Neurology</i> , 2004 , 61, 1898-904		131
337	Clinical findings in a large family with a parkin ex3delta40 mutation. <i>Archives of Neurology</i> , 2004 , 61, 701-4		23
336	Progressive ataxia and palatal tremor (PAPT): clinical and MRI assessment with review of palatal tremors. <i>Brain</i> , 2004 , 127, 1252-68	11.2	107
335	Levodopa and the progression of Parkinson's disease. <i>New England Journal of Medicine</i> , 2004 , 351, 2498-508	5.9	1355
334	Single pulse stimulation of the human subthalamic nucleus facilitates the motor cortex at short intervals. <i>Journal of Neurophysiology</i> , 2004 , 92, 1937-43	3.2	44
333	Involvement of human thalamus in the preparation of self-paced movement. <i>Brain</i> , 2004 , 127, 2717-31	11.2	91
332	Emergence of restless legs syndrome during subthalamic stimulation for Parkinson disease. <i>Neurology</i> , 2004 , 63, 2410-2	6.5	105
331	Thalamic deep brain stimulation activates the cerebellothalamocortical pathway. <i>Neurology</i> , 2004 , 63, 907-9	6.5	56
330	Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. <i>Lancet Neurology</i> , 2004 , 3, 309-16	24.1	256
329	Bilateral globus pallidus stimulation for Huntington's disease. <i>Annals of Neurology</i> , 2004 , 56, 290-4	9.4	179
328	Chorein detection for the diagnosis of chorea-acanthocytosis. <i>Annals of Neurology</i> , 2004 , 56, 299-302	9.4	162
327	Gestes antagonistes in psychogenic dystonia. <i>Movement Disorders</i> , 2004 , 19, 331-2	7	27
326	Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations. <i>Movement Disorders</i> , 2004 , 19, 22-8	7	70
325	Sporadic case of dentatorubral pallidoluysian atrophy with no CAG repeat expansion and no intranuclear inclusions. <i>Movement Disorders</i> , 2004 , 19, 580-3	7	9
324	Rapidly progressive behavioral changes and parkinsonism in a 68-year-old man. <i>Movement Disorders</i> , 2004 , 19, 534-43	7	4
323	Dystonia as a presenting sign of spinocerebellar ataxia type 1. <i>Movement Disorders</i> , 2004 , 19, 586-7	7	30

322	Voluntary control and a wider clinical spectrum of essential palatal tremor. <i>Movement Disorders</i> , 2004 , 19, 717-9	7	19
321	Bilateral globus pallidus internus deep brain stimulation in tardive dyskinesia: a case report. <i>Movement Disorders</i> , 2004 , 19, 969-72	7	80
320	Presentation of Creutzfeldt-Jakob disease as acute corticobasal degeneration syndrome. <i>Movement Disorders</i> , 2004 , 19, 948-9	7	37
319	Subthalamic nucleus deep brain stimulation for parkinson's disease after successful pallidotomy: clinical and electrophysiological observations. <i>Movement Disorders</i> , 2004 , 19, 1209-14	7	43
318	Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. <i>Movement Disorders</i> , 2004 , 19, 656-62	7	208
317	Distribution, type, and origin of Parkin mutations: review and case studies. <i>Movement Disorders</i> , 2004 , 19, 1146-57	7	194
316	Neuronal activity in the globus pallidus of multiple system atrophy patients. <i>Movement Disorders</i> , 2004 , 19, 1485-92	7	6
315	Outcome measures for clinical trials in Parkinson's disease: achievements and shortcomings. <i>Expert Review of Neurotherapeutics</i> , 2004 , 4, 985-93	4.3	9
314	The perioperative management of Parkinson's disease revisited. <i>Neurologic Clinics</i> , 2004 , 22, 367-77	4.5	24
313	Genetic association study of PINK1 coding polymorphisms in Parkinson's disease. <i>Neuroscience Letters</i> , 2004 , 372, 226-9	3.3	28
312	DJ-1 (PARK7) mutations are less frequent than Parkin (PARK2) mutations in early-onset Parkinson disease. <i>Neurology</i> , 2004 , 62, 389-94	6.5	169
311	Primary dystonia is more responsive than secondary dystonia to pallidal interventions: outcome after pallidotomy or pallidal deep brain stimulation. <i>Neurosurgery</i> , 2004 , 54, 613-19; discussion 619-21	3.2	224
310	Pallidal deep brain stimulation in cervical dystonia: clinical outcome in four cases. <i>Canadian Journal of Neurological Sciences</i> , 2004 , 31, 328-32	1	61
309	Insights into brain function through the examination of art: the influence of neurodegenerative diseases. <i>NeuroReport</i> , 2004 , 15, 933-7	1.7	8
308	Antidepressants in the treatment of psychosis with comorbid depression in Parkinson disease. <i>Clinical Neuropharmacology</i> , 2004 , 27, 90-2	1.4	22
307	Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists. <i>Archives of Neurology</i> , 2004 , 61, 97-102		152
306	Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease. <i>Journal of Neurosurgery</i> , 2003 , 99, 489-95	3.2	257
305	Short and long latency afferent inhibition in Parkinson's disease. <i>Brain</i> , 2003 , 126, 1883-94	11.2	214

304	Progression of gait, speech and swallowing deficits in progressive supranuclear palsy. <i>Neurology</i> , 2003 , 60, 917-22	6.5	90
303	Subthalamic stimulation for Parkinson's disease--living better electrically?. <i>New England Journal of Medicine</i> , 2003 , 349, 1888-91	59.2	10
302	Stimulation of the subthalamic nucleus in Parkinson's disease does not produce striatal dopamine release. <i>Neurosurgery</i> , 2003 , 53, 1095-102; discussion 1102-5	3.2	69
301	. <i>Current Opinion in Neurology</i> , 2003 , 16, 523-527	7.1	5
300	Long-term follow-up of thalamic deep brain stimulation for essential and parkinsonian tremor. <i>Neurology</i> , 2003 , 61, 1601-4	6.5	174
299	The fragile X premutation presenting as essential tremor. <i>Archives of Neurology</i> , 2003 , 60, 117-21		145
298	The cerebellothalamocortical pathway in essential tremor. <i>Neurology</i> , 2003 , 60, 1985-7	6.5	83
297	Motor cortical stimulation for parkinsonism in multiple system atrophy. <i>Archives of Neurology</i> , 2003 , 60, 1554-8		36
296	Mutations in the epsilon-sarcoglycan gene found to be uncommon in seven myoclonus-dystonia families. <i>Neurology</i> , 2003 , 61, 244-6	6.5	39
295	Hemiballism: revisiting a classic disorder. <i>Lancet Neurology</i> , 2003 , 2, 661-8	24.1	173
294	Acute effect of transcutaneous electrical nerve stimulation on tremor. <i>Movement Disorders</i> , 2003 , 18, 191-4	7	11
293	Neurodegenerative disease and the evolution of art: the effects of presumed corticobasal degeneration in a professional artist. <i>Movement Disorders</i> , 2003 , 18, 294-302	7	28
292	Corticobasal degeneration syndrome with basal ganglia calcification: Fahr's disease as a corticobasal look-alike?. <i>Movement Disorders</i> , 2003 , 18, 351-352	7	1
291	Unique form of propriospinal myoclonus as a possible complication of an enteropathogenic toxin. <i>Movement Disorders</i> , 2003 , 18, 942-8	7	17
290	Dopa-responsive dystonia presenting with prominent isolated bilateral resting leg tremor: Evidence for a role of parkin?. <i>Movement Disorders</i> , 2003 , 18, 1070-1072	7	6
289	Corticobasal degeneration: selected developments. <i>Movement Disorders</i> , 2003 , 18 Suppl 6, S51-6	7	34
288	Deep brain stimulation for Parkinson's disease dissociates mood and motor circuits: a functional MRI case study. <i>Movement Disorders</i> , 2003 , 18, 1508-16	7	160
287	Posttraumatic painful torticollis. <i>Movement Disorders</i> , 2003 , 18, 1482-91	7	68

286	Pure cerebello-olivary degeneration of Marie, Foix, and Alajouanine presenting with progressive cerebellar ataxia, cognitive decline, and chorea. <i>Movement Disorders</i> , 2003 , 18, 1550-4	7	12
285	Pallidal neuronal activity: implications for models of dystonia. <i>Annals of Neurology</i> , 2003 , 53, 480-8	9.4	223
284	Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. <i>Annals of Neurology</i> , 2003 , 54 Suppl 5, S15-9	9.4	423
283	Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. <i>Annals of Neurology</i> , 2003 , 54, 93-101	9.4	691
282	Benign hereditary chorea: clinical, genetic, and pathological findings. <i>Annals of Neurology</i> , 2003 , 54, 244-7	9.4	81
281	Early-onset Parkinson's disease caused by a compound heterozygous DJ-1 mutation. <i>Annals of Neurology</i> , 2003 , 54, 271-4	9.4	202
280	Psychogenic movement disorders. <i>Canadian Journal of Neurological Sciences</i> , 2003 , 30 Suppl 1, S94-100	1	67
279	Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. <i>Neurology</i> , 2003 , 60, 69-73	6.5	674
278	Involvement of the human subthalamic nucleus in movement preparation. <i>Neurology</i> , 2003 , 61, 1538-45	6.5	50
277	Natural history of Oppenheim's dystonia (DYT1) in Israel. <i>Journal of Child Neurology</i> , 2003 , 18, 325-30	2.5	27
276	Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. <i>Annals of Neurology</i> , 2002 , 51, 604-12	9.4	227
275	Role of SCA2 mutations in early- and late-onset dopa-responsive parkinsonism. <i>Annals of Neurology</i> , 2002 , 52, 257-8; author reply 258	9.4	10
274	Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. <i>Movement Disorders</i> , 2002 , 17, 303-12	7	159
273	Deep brain stimulation for Parkinson's disease: patient selection and evaluation. <i>Movement Disorders</i> , 2002 , 17 Suppl 3, S94-101	7	121
272	Management of Parkinson's disease: An evidence-based review. <i>Movement Disorders</i> , 2002 , 17, i-i	7	15
271	Simultaneous repetitive movements following pallidotomy or subthalamic deep brain stimulation in patients with Parkinson's disease. <i>Experimental Brain Research</i> , 2002 , 147, 322-31	2.3	12
270	Effects of subthalamic nucleus stimulation on motor cortex excitability in Parkinson's disease. <i>Neurology</i> , 2002 , 58, 1665-72	6.5	115
269	Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. <i>Neurology</i> , 2002 , 58, 11-7	6.5	270

268	Predicting motor decline and disability in Parkinson disease: a systematic review. <i>Archives of Neurology</i> , 2002 , 59, 1724-8		146
267	Localization of clinically effective stimulating electrodes in the human subthalamic nucleus on magnetic resonance imaging. <i>Journal of Neurosurgery</i> , 2002 , 97, 1152-66	3.2	222
266	Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review. <i>Neurology</i> , 2002 , 59, 1292; author reply 1292	6.5	
265	A novel locus for inherited myoclonus-dystonia on 18p11. <i>Neurology</i> , 2002 , 59, 1183-6	6.5	114
264	Phenocopies in a large GCH1 mutation positive family with dopa responsive dystonia: confusing the picture?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2002 , 72, 801-4	5.5	24
263	Subthalamic DBS replaces levodopa in Parkinson's disease. <i>Neurology</i> , 2002 , 59, 1293-4; author reply 1294	6.5	10
262	A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. <i>Archives of Neurology</i> , 2002 , 59, 1937-43		470
261	Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. <i>JAMA - Journal of the American Medical Association</i> , 2002 , 287, 455-63	27.4	408
260	Long-term hardware-related complications of deep brain stimulation. <i>Neurosurgery</i> , 2002 , 50, 1268-74; discussion 1274-6	3.2	272
259	Dependence of subthalamic nucleus oscillations on movement and dopamine in Parkinson's disease. <i>Brain</i> , 2002 , 125, 1196-209	11.2	545
258	Treatment of excessive daytime sleepiness in patients with Parkinson's disease with modafinil. <i>Clinical Neuropharmacology</i> , 2002 , 25, 111-4	1.4	108
257	Long-term Hardware-related Complications of Deep Brain Stimulation. <i>Neurosurgery</i> , 2002 , 50, 1268-1276		196
256	Neonatal ablation of the nigrostriatal dopamine pathway does not influence limb development in rats. <i>Experimental Neurology</i> , 2002 , 177, 547-56	5.7	1
255	Effects of acute stimulation through contacts placed on the motor cortex for chronic stimulation. <i>Clinical Neurophysiology</i> , 2002 , 113, 635-41	4.3	33
254	Pathophysiology of the Internal Segment of the Globus Pallidus in Parkinson's Disease. <i>Advances in Behavioral Biology</i> , 2002 , 15-21		
253	Sleepiness and Sleep Attacks in Parkinson's Disease. <i>Advances in Behavioral Biology</i> , 2002 , 385-390		
252	Acute Effects of Levodopa and Pallidotomy on Bimanual Repetitive Arm Movements in Patients with Parkinson's Disease. <i>Advances in Behavioral Biology</i> , 2002 , 43-50		
251	Myoclonus in parkinsonian disorders. <i>Advances in Neurology</i> , 2002 , 89, 77-83		6

250	Essential palatal tremor. <i>Movement Disorders</i> , 2001 , 16, 1202-3	7	3
249	Orthostatic tremor arises from an oscillator in the posterior fossa. <i>Movement Disorders</i> , 2001 , 16, 272-9	7	84
248	69-year-old man with gait disturbance and Parkinsonism. <i>Movement Disorders</i> , 2001 , 16, 548-61	7	1
247	Functional correlates of pallidal stimulation for Parkinson's disease. <i>Annals of Neurology</i> , 2001 , 49, 155-64	6.4	96
246	Inherited myoclonus-dystonia: evidence supporting genetic heterogeneity. <i>Movement Disorders</i> , 2001 , 16, 106-10	7	37
245	Acute onset dystonic camptocormia caused by lenticular lesions. <i>Movement Disorders</i> , 2001 , 16, 177-80	7	57
244	Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. <i>Neurology</i> , 2001 , 56, 1702-6	6.5	358
243	Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. <i>New England Journal of Medicine</i> , 2001 , 345, 956-63	59.2	1283
242	Botulinum toxin for simple motor tics: a randomized, double-blind, controlled clinical trial. <i>Neurology</i> , 2001 , 56, 605-10	6.5	181
241	Effects of internal globus pallidus stimulation on motor cortex excitability. <i>Neurology</i> , 2001 , 56, 716-23	6.5	78
240	The importance of gene dosage studies: mutational analysis of the parkin gene in early-onset parkinsonism. <i>Human Molecular Genetics</i> , 2001 , 10, 1649-56	5.6	106
239	Networks mediating the clinical effects of pallidal brain stimulation for Parkinson's disease: a PET study of resting-state glucose metabolism. <i>Brain</i> , 2001 , 124, 1601-9	11.2	109
238	Potentials recorded at the scalp by stimulation near the human subthalamic nucleus. <i>Clinical Neurophysiology</i> , 2001 , 112, 431-7	4.3	112
237	Impairment of motor cortex activation and deactivation in Parkinson's disease. <i>Clinical Neurophysiology</i> , 2001 , 112, 600-7	4.3	71
236	Effects of apomorphine on subthalamic nucleus and globus pallidus internus neurons in patients with Parkinson's disease. <i>Journal of Neurophysiology</i> , 2001 , 86, 249-60	3.2	236
235	Lidocaine and muscimol microinjections in subthalamic nucleus reverse Parkinsonian symptoms. <i>Brain</i> , 2001 , 124, 2105-18	11.2	141
234	Amoxapine shows an antipsychotic effect but worsens motor function in patients with Parkinson's disease and psychosis. <i>Clinical Neuropharmacology</i> , 2001 , 24, 242-4	1.4	15
233	Deep brain stimulator electrodes used for lesioning: proof of principle. <i>Neurosurgery</i> , 2001 , 49, 363-7; discussion 367-9	3.2	42

232	Psychiatric outcome in patients with a psychogenic movement disorder: a prospective study. <i>Neuropsychiatry, Neuropsychology and Behavioral Neurology</i> , 2001 , 14, 169-76		113
231	Update on the treatment of tics. <i>Advances in Neurology</i> , 2001 , 85, 355-62		4
230	Evaluation of the role of the D2 dopamine receptor in myoclonus dystonia. <i>Annals of Neurology</i> , 2000 , 47, 369-373	9.4	34
229	An investigation of the effects of subthalamic nucleus stimulation on acoustic measures of voice. <i>Movement Disorders</i> , 2000 , 15, 1132-8	7	91
228	Botulinum toxin for essential tremor of the voice with multiple anatomical sites of tremor: a crossover design study of unilateral versus bilateral injection. <i>Laryngoscope</i> , 2000 , 110, 1366-74	3.6	103
227	Late adult onset chorea with typical pathology of Hallervorden-Spatz syndrome. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2000 , 69, 392-5	5.5	23
226	Relationship of lesion location to cognitive outcome following microelectrode-guided pallidotomy for Parkinson's disease: support for the existence of cognitive circuits in the human pallidum. <i>Brain</i> , 2000 , 123 (Pt 4), 746-58	11.2	79
225	Long-term follow-up of unilateral pallidotomy in advanced Parkinson's disease. <i>New England Journal of Medicine</i> , 2000 , 342, 1708-14	59.2	239
224	Surgery for Parkinson disease: A critical evaluation of the state of the art. <i>Archives of Neurology</i> , 2000 , 57, 1118-25		72
223	Neuropsychological outcome of GPi pallidotomy and GPi or STN deep brain stimulation in Parkinson's disease. <i>Brain and Cognition</i> , 2000 , 42, 324-47	2.7	229
222	A Major Locus for Myoclonus-Dystonia Maps to Chromosome 7q in Eight Families*. <i>American Journal of Human Genetics</i> , 2000 , 67, 1314-1319	11	
221	Neuropsychological consequences of chronic bilateral stimulation of the subthalamic nucleus in Parkinson's disease. <i>Brain</i> , 2000 , 123 (Pt 10), 2091-108	11.2	411
220	A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. <i>New England Journal of Medicine</i> , 2000 , 342, 1484-91	59.2	1253
219	Corticobasal ganglionic degeneration and/or frontotemporal dementia?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2000 , 69, 705-705	5.5	2
218	Clinical diagnostic criteria. <i>Advances in Neurology</i> , 2000 , 82, 29-34		16
217	Parkinsonism in corticobasal degeneration. <i>Advances in Neurology</i> , 2000 , 82, 83-9		2
216	Surgery for levodopa-induced dyskinesias. <i>Annals of Neurology</i> , 2000 , 47, S193-9; discussion S199-202	9.4	29
215	Relationship of lesion location to clinical outcome following microelectrode-guided pallidotomy for Parkinson's disease. <i>Brain</i> , 1999 , 122 (Pt 3), 405-16	11.2	122

214	Intracranial hypotension with parkinsonism, ataxia, and bulbar weakness. <i>Archives of Neurology</i> , 1999 , 56, 869-72		99
213	Comparative effects of unilateral and bilateral subthalamic nucleus deep brain stimulation. <i>Neurology</i> , 1999 , 53, 561-6	6.5	220
212	Dementia as the most common presentation of cortical-basal ganglionic degeneration. <i>Neurology</i> , 1999 , 53, 1969-74	6.5	188
211	Historical and clinical features of psychogenic tremor: a review of 70 cases. <i>Canadian Journal of Neurological Sciences</i> , 1999 , 26, 190-5	1	89
210	Variability in lesion location after microelectrode-guided pallidotomy for Parkinson's disease: anatomical, physiological, and technical factors that determine lesion distribution. <i>Journal of Neurosurgery</i> , 1999 , 90, 468-77	3.2	34
209	Clinical features differentiating patients with postmortem confirmed progressive supranuclear palsy and corticobasal degeneration. <i>Journal of Neurology</i> , 1999 , 246 Suppl 2, 111-5	5.5	65
208	Posteroventral medial pallidotomy in Parkinson's disease. <i>Journal of Neurology</i> , 1999 , 246 Suppl 2, 1128-45	4.5	31
207	Essential palatal tremor: evidence of heterogeneity based on clinical features and response to Sumatriptan. <i>Movement Disorders</i> , 1999 , 14, 179-80	7	25
206	Factor analysis of the motor section of the unified Parkinson's disease rating scale during the off-state. <i>Movement Disorders</i> , 1999 , 14, 585-9	7	62
205	Motor neuron disease-inclusion dementia presenting as cortical-basal ganglionic degeneration. <i>Movement Disorders</i> , 1999 , 14, 674-80	7	53
204	Syringomyelic dystonia and athetosis. <i>Movement Disorders</i> , 1999 , 14, 684-8	7	39
203	Dose-induced penile erections in response to ropinirole therapy for Parkinson's disease. <i>Movement Disorders</i> , 1999 , 14, 701-2	7	32
202	Consensus statement on the diagnosis of multiple system atrophy. <i>Journal of the Neurological Sciences</i> , 1999 , 163, 94-8	3.2	1006
201	Cortical reflex myoclonus studied with cortical electrodes. <i>Clinical Neurophysiology</i> , 1999 , 110, 1521-30	4.3	9
200	Neurophysiological effects of stimulation through electrodes in the human subthalamic nucleus. <i>Brain</i> , 1999 , 122 (Pt 10), 1919-31	11.2	138
199	Globus pallidus deep brain stimulation for generalized dystonia: clinical and PET investigation. <i>Neurology</i> , 1999 , 53, 871-4	6.5	308
198	Treatment of early Parkinson's disease. <i>Canadian Journal of Neurological Sciences</i> , 1999 , 26 Suppl 2, S39-44		4
197	Posteroventral medial pallidotomy in advanced Parkinson's disease. <i>Advances in Neurology</i> , 1999 , 80, 575-83		7

196	Posteroventral medial pallidotomy in Parkinson's disease. <i>Journal of Neurology</i> , 1999 , 246, s028-s041	5.5	
195	Neurophysiological identification of the subthalamic nucleus in surgery for Parkinson's disease. <i>Annals of Neurology</i> , 1998 , 44, 622-8	9.4	580
194	New use for an old drug: amantadine benefits levodopa-induced dyskinesia. <i>Movement Disorders</i> , 1998 , 13, 851	7	44
193	Consensus statement on the diagnosis of multiple system atrophy. American Autonomic Society and American Academy of Neurology. <i>Clinical Autonomic Research</i> , 1998 , 8, 359-62	4.3	248
192	New developments in understanding the etiology of Parkinson's disease and in its treatment. <i>Current Opinion in Neurobiology</i> , 1998 , 8, 783-90	7.6	74
191	Pallidotomy for tremor. <i>Movement Disorders</i> , 1998 , 13 Suppl 3, 107-10	7	13
190	Corticobasal ganglionic degeneration and progressive supranuclear palsy presenting with cognitive decline. <i>Brain Pathology</i> , 1998 , 8, 355-65	6	74
189	Parkinson's disease. First of two parts. <i>New England Journal of Medicine</i> , 1998 , 339, 1044-53	59.2	1636
188	Parkinson's disease. Second of two parts. <i>New England Journal of Medicine</i> , 1998 , 339, 1130-43	59.2	972
187	Double-blind evaluation of subthalamic nucleus deep brain stimulation in advanced Parkinson's disease. <i>Neurology</i> , 1998 , 51, 850-5	6.5	547
186	Neuropsychological consequences of posteroventral pallidotomy for the treatment of Parkinson's disease. <i>Neurology</i> , 1998 , 51, 207-15	6.5	142
185	Immediate motor effects of stimulation through electrodes implanted in the human globus pallidus. <i>Stereotactic and Functional Neurosurgery</i> , 1998 , 70, 1-18	1.6	41
184	Pallidal stimulation in Parkinson's disease patients with a prior unilateral pallidotomy. <i>Canadian Journal of Neurological Sciences</i> , 1998 , 25, 300-5	1	69
183	Gender-related penetrance and de novo GTP-cyclohydrolase I gene mutations in dopa-responsive dystonia. <i>Neurology</i> , 1998 , 50, 1015-20	6.5	121
182	Microelectrode recordings define the ventral posteromedial pallidotomy target. <i>Stereotactic and Functional Neurosurgery</i> , 1998 , 71, 153-63	1.6	21
181	Pallidotomy for Parkinson's Disease. <i>Neurosurgery Clinics of North America</i> , 1998 , 9, 325-336	4	40
180	Surgical treatment of dystonia. <i>Advances in Neurology</i> , 1998 , 78, 185-98		13
179	Effect of GPi pallidotomy on neuropsychological function in Parkinson's Disease. <i>Archives of Clinical Neuropsychology</i> , 1997 , 12, 419-419	2.7	2

178	Olfactory dysfunction in familial parkinsonism. <i>Neurology</i> , 1997 , 49, 1262-7	6.5	74
177	Pallidotomy increases cortical inhibition in Parkinson's disease. <i>Canadian Journal of Neurological Sciences</i> , 1997 , 24, 133-6	1	16
176	Posteroventral medial pallidotomy in advanced Parkinson's disease. <i>New England Journal of Medicine</i> , 1997 , 337, 1036-42	59.2	392
175	Tourette syndrome. Secondary tic disorders. <i>Neurologic Clinics</i> , 1997 , 15, 309-31	4.5	55
174	Dystonia in progressive supranuclear palsy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1997 , 62, 352-6	5.5	83
173	Pallidal and thalamic surgery for Parkinson's disease. <i>Experimental Neurology</i> , 1997 , 144, 35-40	5.7	23
172	Reversible dissociation of sensitivity to dynamic stimuli in Parkinson's disease: is magnocellular function essential to reading motion-defined letters?. <i>Vision Research</i> , 1997 , 37, 3531-4	2.1	15
171	Coexistence of tics and parkinsonism: evidence for non-dopaminergic mechanisms in tic pathogenesis. <i>Neurology</i> , 1997 , 49, 1699-701	6.5	30
170	Globus pallidus stimulation activates the cortical motor system during alleviation of parkinsonian symptoms. <i>Nature Medicine</i> , 1997 , 3, 671-4	50.5	184
169	Identification and characterization of neurons with tremor-frequency activity in human globus pallidus. <i>Experimental Brain Research</i> , 1997 , 113, 557-63	2.3	160
168	Neuropsychological and behavioral changes and weight gain after medial pallidotomy. <i>Annals of Neurology</i> , 1997 , 41, 834-6	9.4	42
167	High-frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor. <i>Annals of Neurology</i> , 1997 , 42, 292-9	9.4	451
166	Effects of apomorphine on globus pallidus neurons in parkinsonian patients. <i>Annals of Neurology</i> , 1997 , 42, 767-75	9.4	174
165	Essential myoclonus and myoclonic dystonia. <i>Movement Disorders</i> , 1997 , 12, 127	7	22
164	Adult-onset subacute sclerosing panencephalitis: case reports and review of the literature. <i>Movement Disorders</i> , 1997 , 12, 342-53	7	82
163	Reflex myoclonus in cortical-basal ganglionic degeneration involves a transcortical pathway. <i>Movement Disorders</i> , 1997 , 12, 360-9	7	36
162	Teaching tape for the motor section of the Toronto Western Spasmodic Torticollis Scale. <i>Movement Disorders</i> , 1997 , 12, 570-5	7	147
161	Inhibition of voluntary activity by thalamic stimulation in humans: relevance for the control of tremor. <i>Movement Disorders</i> , 1997 , 12, 727-37	7	71

160	Globus pallidus internus pallidotomy for generalized dystonia. <i>Movement Disorders</i> , 1997 , 12, 865-70	7	329
159	The effects of pallidotomy on Parkinson's disease: study design and assessment techniques. <i>Acta Neurochirurgica Supplementum</i> , 1997 , 68, 24-8	1.7	7
158	Cortical Degeneration in Progressive Supranuclear Palsy. A Comparison with Cortical-Basal Ganglionic Degeneration. <i>Journal of Neuropathology and Experimental Neurology</i> , 1997 , 56, 726-734	3.1	71
157	Microelectrode recording-guided posteroventral pallidotomy in patients with Parkinson's disease. <i>Advances in Neurology</i> , 1997 , 74, 167-74		14
156	Medial pallidotomy in late-stage Parkinson's disease and striatonigral degeneration. <i>Advances in Neurology</i> , 1997 , 74, 199-211		10
155	Perioperative problems in Parkinson's disease and their management: apomorphine with rectal domperidone. <i>Canadian Journal of Neurological Sciences</i> , 1996 , 23, 198-203	1	35
154	Normal distribution of apolipoprotein E alleles in progressive supranuclear palsy. <i>Neurology</i> , 1996 , 46, 1156-7	6.5	21
153	Prevalence of focal dystonias in the western area of Tottori Prefecture in Japan. <i>Movement Disorders</i> , 1996 , 11, 342-3	7	1
152	Idiopathic generalized myokymia (Isaacs' syndrome) with hand posturing resembling dystonia. <i>Movement Disorders</i> , 1996 , 11, 448-9	7	14
151	Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group. <i>Annals of Neurology</i> , 1996 , 39, 37-45	9.4	286
150	Unusual clinical presentations of cortical-basal ganglionic degeneration. <i>Annals of Neurology</i> , 1996 , 40, 893-900	9.4	113
149	Atypical dopa responsive parkinsonism in a patient with megalencephaly, midbrain Lewy body disease, and some pathological features of Hallervorden-Spatz disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1996 , 61, 523-7	5.5	12
148	Remoxipride in the treatment of levodopa-induced psychosis. <i>Journal of Clinical Psychopharmacology</i> , 1996 , 16, 395-9	1.7	9
147	Motor effects of stimulating the human cerebellar thalamus. <i>Journal of Physiology</i> , 1995 , 489 (Pt 1), 287-98	3.9	21
146	Factors predictive of the need for levodopa therapy in early, untreated Parkinson's disease. The Parkinson Study Group. <i>Archives of Neurology</i> , 1995 , 52, 565-70		48
145	Psychogenic parkinsonism. <i>Archives of Neurology</i> , 1995 , 52, 802-10		116
144	Evidence for inter-generational instability in the CAG repeat in the MJD1 gene and for conserved haplotypes at flanking markers amongst Japanese and Caucasian subjects with Machado-Joseph disease. <i>Human Molecular Genetics</i> , 1995 , 4, 1137-46	5.6	129
143	Effect of GPi pallidotomy on motor function in Parkinson's disease. <i>Lancet, The</i> , 1995 , 346, 1383-7	40	547

142	Psychogenic dystonia: a review of 18 cases. <i>Canadian Journal of Neurological Sciences</i> , 1995 , 22, 136-43	1	118
141	Dopa-responsive parkinsonism phenotype of Machado-Joseph disease: confirmation of 14q CAG expansion. <i>Annals of Neurology</i> , 1995 , 38, 684-7	9.4	105
140	Gestes antagonistes in the suppression of tics: "tricks for tics". <i>Movement Disorders</i> , 1995 , 10, 226-8	7	14
139	"Weight-holding tremor": an unusual task-specific form of essential tremor?. <i>Movement Disorders</i> , 1995 , 10, 228-9	7	4
138	The classification of akathisia. <i>Movement Disorders</i> , 1995 , 10, 235-7	7	7
137	Case 1, 1995: psychosis, dementia, chorea, ataxia, and supranuclear gaze dysfunction. <i>Movement Disorders</i> , 1995 , 10, 257-62	7	21
136	Hemiatrophy, juvenile-onset exertional alternating leg paresis, hypotonia, and hemidystonia and adult-onset hemiparkinsonism: the spectrum of hemiparkinsonism-hemiatrophy syndrome. <i>Movement Disorders</i> , 1995 , 10, 489-95	7	29
135	The core assessment program for intracerebral transplantation. <i>Movement Disorders</i> , 1995 , 10, 527-8	7	30
134	Chronic acquired hepatocerebral degeneration: case reports and new insights. <i>Movement Disorders</i> , 1995 , 10, 714-22	7	72
133	Comparison of botulinum toxin injection procedures in adductor spasmodic dysphonia. <i>The Journal of Otolaryngology</i> , 1995 , 24, 345-51		23
132	Severe evening dyskinesias in advanced Parkinson's disease: clinical description, relation to plasma levodopa, and treatment. <i>Movement Disorders</i> , 1994 , 9, 173-7	7	13
131	Withdrawal akathisia: case reports and a proposed classification of chronic akathisia. <i>Movement Disorders</i> , 1994 , 9, 188-92	7	29
130	What is it? Case 1, 1994: rapidly progressive aphasia, apraxia, dementia, myoclonus, and parkinsonism. <i>Movement Disorders</i> , 1994 , 9, 358-66	7	16
129	Utility of an objective dyskinesia rating scale for Parkinson's disease: inter- and intrarater reliability assessment. <i>Movement Disorders</i> , 1994 , 9, 390-4	7	262
128	Parkinsonian syndromes associated with hydrocephalus: case reports, a review of the literature, and pathophysiological hypotheses. <i>Movement Disorders</i> , 1994 , 9, 508-20	7	168
127	Homozygous inheritance of the Machado-Joseph disease gene. <i>Annals of Neurology</i> , 1994 , 36, 443-7	9.4	73
126	Striatonigral degeneration: iron deposition in putamen correlates with the slit-like void signal of magnetic resonance imaging. <i>Canadian Journal of Neurological Sciences</i> , 1994 , 21, 311-8	1	50
125	Differential neuronal activity in segments of globus pallidus in Parkinson's disease patients. <i>NeuroReport</i> , 1994 , 5, 1533-7	1.7	226

124	Parietal Pick's disease mimicking cortical-basal ganglionic degeneration. <i>Neurology</i> , 1994 , 44, 1436-40	6.5	71
123	Movement sequencing disorders in Parkinson's disease. <i>International Journal of Neuroscience</i> , 1993 , 73, 183-94	2	41
122	The spectrum of levodopa-related fluctuations in Parkinson's disease. <i>Neurology</i> , 1993 , 43, 1459-64	6.5	128
121	Flunarizine in essential tremor. <i>Clinical Neuropharmacology</i> , 1993 , 16, 460-3	1.4	15
120	"Signing tics"--insights into the pathophysiology of symptoms in Tourette's syndrome. <i>Annals of Neurology</i> , 1993 , 33, 212-5	9.4	33
119	Unilateral versus bilateral botulinum toxin injections in spasmodic dysphonia: acoustic and perceptual results. <i>The Journal of Otolaryngology</i> , 1993 , 22, 171-5		34
118	Stimulus-sensitive myoclonus in akinetic-rigid syndromes. <i>Brain</i> , 1992 , 115 (Pt 6), 1875-88	11.2	73
117	Cortical basal ganglionic degeneration presenting with "progressive loss of speech output and orofacial dyspraxia". <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1992 , 55, 1101	5.5	37
116	Can the Lombard effect be used to improve low voice intensity in Parkinson's disease?. <i>International Journal of Language and Communication Disorders</i> , 1992 , 27, 121-7	2.9	36
115	Tizanidine in cranial dystonia. <i>Clinical Neuropharmacology</i> , 1992 , 15, 142-7	1.4	10
114	Stiff-Person Syndrome. <i>Canadian Journal of Neurological Sciences</i> , 1992 , 19, 383-388	1	8
113	What is it? Case 1, 1992: progressive gait deterioration, peripheral neuropathy, optic atrophy, bradykinesia, and dystonia in a young girl. <i>Movement Disorders</i> , 1992 , 7, 373-9	7	
112	Clinical phenomenology of tic disorders selected aspects. <i>Advances in Neurology</i> , 1992 , 58, 25-32		17
111	What is it? Case 1, 1991: a severe and fatal systemic illness first presenting with a movement disorder. <i>Movement Disorders</i> , 1991 , 6, 362-70	7	4
110	Patient perception of tics and other movement disorders. <i>Neurology</i> , 1991 , 41, 223-8	6.5	113
109	Subcognitive processing in the frontocaudate "complex loop": the role of the striatum. <i>Alzheimer Disease and Associated Disorders</i> , 1990 , 4, 150-60	2.5	16
108	Clinical differences between metoclopramide- and antipsychotic-induced tardive dyskinesias. <i>Canadian Journal of Neurological Sciences</i> , 1990 , 17, 137-9	1	10
107	Potential benefits of dopamine striatal implant. <i>Annals of Neurology</i> , 1990 , 27, 109-10	9.4	2

106	Dopa-responsive parkinsonism with normal 6[18F]-fluorodopa positron emission tomography scans. <i>Annals of Neurology</i> , 1990 , 28, 592-3	9.4	6
105	Parkinsonism in alcohol withdrawal: a follow-up study. <i>Movement Disorders</i> , 1990 , 5, 36-9	7	30
104	Psychogenic dyskinesias in patients with organic movement disorders. <i>Movement Disorders</i> , 1990 , 5, 127-33	69	
103	Hypoxic-ischemic damage of the basal ganglia. Case reports and a review of the literature. <i>Movement Disorders</i> , 1990 , 5, 219-24	7	118
102	What is it? Case 1, 1990: progressive unilateral rigidity, bradykinesia, tremulousness, and apraxia, leading to fixed postural deformity of the involved limb. <i>Movement Disorders</i> , 1990 , 5, 341-51	7	22
101	Multiple sclerosis occurring with paroxysmal unilateral dystonia. <i>Movement Disorders</i> , 1990 , 5, 352-3	7	45
100	CQA 206-291 in Parkinson's disease: an acute single escalating dosage study. <i>Canadian Journal of Neurological Sciences</i> , 1990 , 17, 416-9	1	2
99	Cortical-basal ganglionic degeneration. <i>Neurology</i> , 1990 , 40, 1203-12	6.5	422
98	Hemiballism-hemichorea. <i>Archives of Neurology</i> , 1990 , 47, 619-20		2
97	Memory and learning in early Parkinson's disease: evidence for a "frontal lobe syndrome". <i>Brain and Cognition</i> , 1990 , 13, 211-32	2.7	204
96	Frozen shoulder and other shoulder disturbances in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1989 , 52, 63-6	5.5	109
95	Posttraumatic movement disorders: a review. <i>Movement Disorders</i> , 1989 , 4, 20-36	7	104
94	Pain in Gilles de la Tourette syndrome and related tic disorders. <i>Canadian Journal of Neurological Sciences</i> , 1989 , 16, 439-41	1	20
93	Anticholinergic Drugs and Amantadine in the Treatment of Parkinson's Disease. <i>Handbook of Experimental Pharmacology</i> , 1989 , 307-323	3.2	14
92	Hemiballism in multiple sclerosis. <i>Movement Disorders</i> , 1988 , 3, 88-94	7	63
91	Procedural learning and neostriatal dysfunction in man. <i>Brain</i> , 1988 , 111 (Pt 4), 941-59	11.2	477
90	Afferents contributing to the exaggerated long latency reflex response to electrical stimulation in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1988 , 51, 1405-10	5.5	39
89	Botulinum toxin injections in the treatment of blepharospasm, hemifacial spasm, and eyelid fasciculations. <i>Canadian Journal of Neurological Sciences</i> , 1988 , 15, 276-80	1	45

88	Idiopathic Parkinson's disease: revised concepts of cognitive and affective status. <i>Canadian Journal of Neurological Sciences</i> , 1988 , 15, 106-13	1	14
87	Dopamine agonists and antagonists in the treatment of idiopathic dystonia. <i>Advances in Neurology</i> , 1988 , 50, 561-70		18
86	Secondary dystonia. <i>Advances in Neurology</i> , 1988 , 50, 9-33		41
85	Positron tomography in dystonia. <i>Advances in Neurology</i> , 1988 , 50, 249-53		13
84	Cranial dystonia, blepharospasm and hemifacial spasm: clinical features and treatment, including the use of botulinum toxin. <i>Cmaj</i> , 1988 , 139, 837-44	3.5	16
83	Parkinson's disease. Cognitive changes in relation to treatment response. <i>Brain</i> , 1987 , 110 (Pt 1), 35-51	11.2	86
82	Progressive dystonia with bilateral putaminal hypodensities. <i>Archives of Neurology</i> , 1987 , 44, 1184-7		30
81	Update on dopamine agonists in Parkinson's disease: "beyond bromocriptine". <i>Canadian Journal of Neurological Sciences</i> , 1987 , 14, 474-82	1	11
80	Manipulating the dopaminergic system in Parkinson's disease 1987 , 32, 51-76		5
79	A rostrocaudal gradient for aromatic acid decarboxylase in the human striatum. <i>Canadian Journal of Neurological Sciences</i> , 1987 , 14, 444-7	1	30
78	Regional cerebral glucose metabolism in SLE chorea: further evidence that striatal hypometabolism is not a correlate of chorea. <i>Movement Disorders</i> , 1987 , 2, 201-10	7	57
77	Sudden confusion with levodopa withdrawal. <i>Movement Disorders</i> , 1987 , 2, 223	7	2
76	What is it? Case 1, 1987: unusual tremors, bradykinesia, and cerebral lucencies. <i>Movement Disorders</i> , 1987 , 2, 321-38	7	4
75	Association between familial tremor and Parkinson's disease. <i>Annals of Neurology</i> , 1986 , 19, 306-7	9.4	11
74	Levodopa dose-related fluctuations in presumed olivopontocerebellar atrophy. <i>Movement Disorders</i> , 1986 , 1, 93-102	7	10
73	Parkinson's disease and depression. A critical re-evaluation. <i>Brain</i> , 1986 , 109 (Pt 2), 279-92	11.2	135
72	Familial dystonia and visual failure with striatal CT lucencies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1986 , 49, 500-9	5.5	40
71	Frontal lobe dysfunction in Parkinson's disease. The cortical focus of neostriatal outflow. <i>Brain</i> , 1986 , 109 (Pt 5), 845-83	11.2	817

70	Painful Parkinson's disease. <i>Lancet, The</i> , 1986 , 1, 1366-9	40	133
69	High dose anticholinergic therapy in adult dystonia. <i>Canadian Journal of Neurological Sciences</i> , 1986 , 13, 42-6	1	33
68	Persistent hemiballismus with lesions outside the subthalamic nucleus. <i>Canadian Journal of Neurological Sciences</i> , 1985 , 12, 125-8	1	41
67	Dopamine agonists in the treatment of dystonia. <i>Clinical Neuropharmacology</i> , 1985 , 8, 38-57	1.4	22
66	Coexistence of idiopathic Parkinson's disease and Creutzfeldt-Jakob disease. <i>Canadian Journal of Neurological Sciences</i> , 1985 , 12, 272-3	1	16
65	The anatomical basis of symptomatic hemidystonia. <i>Brain</i> , 1985 , 108 (Pt 2), 463-83	11.2	589
64	Dementia prevalence in Parkinson's disease. <i>Lancet, The</i> , 1985 , 1, 1037	40	28
63	Striatal dopamine distribution in parkinsonian patients during life. <i>Journal of the Neurological Sciences</i> , 1985 , 69, 223-30	3.2	165
62	Treatment of Parkinson's disease with agents other than levodopa and dopamine agonists: controversies and new approaches. <i>Canadian Journal of Neurological Sciences</i> , 1984 , 11, 210-20	1	34
61	Focal paroxysmal kinesigenic choreoathetosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1984 , 47, 1057-8	5.5	6
60	Lithium and parkinsonism. <i>Annals of Neurology</i> , 1984 , 15, 214	9.4	13
59	Diagnostic importance of immunological markers in lymphoma involving the central nervous system. <i>Annals of Neurology</i> , 1984 , 16, 668-72	9.4	20
58	A double-blind trial of clonazepam in benign essential tremor. <i>Clinical Neuropharmacology</i> , 1984 , 7, 83-8	1.4	54
57	Parkinson's disease in 1984: an update. <i>Cmaj</i> , 1984 , 131, 1031-7		6
56	Long latency between the onset of motor and vocal tics in Tourette's syndrome. <i>Annals of Neurology</i> , 1983 , 14, 693-4	9.4	6
55	Spasmodic dysphonia in Gilles de la Tourette's disease. <i>Archives of Neurology</i> , 1983 , 40, 51-2		9
54	Dopa dose-dependent sexual deviation. <i>British Journal of Psychiatry</i> , 1983 , 142, 296-8	5.4	54
53	Postanoxic symptomatic oscillatory myoclonus. <i>Neurology</i> , 1983 , 33, 240-3	6.5	40

52	Myoclonic dystonia. <i>Neurology</i> , 1983 , 33, 825-30	6.5	119
51	Pharmacology of cranial dystonia. <i>Neurology</i> , 1983 , 33, 1100-2	6.5	16
50	Early onset of the "on-off" phenomenon in children with symptomatic Parkinsonism. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1982 , 45, 823-5	5.5	29
49	Insulin-induced hypoglycaemia does not abolish chorea. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1982 , 45, 936-7	5.5	2
48	Alpha methylparatyrosine and tetrabenazine in movement disorders. <i>Clinical Neuropharmacology</i> , 1982 , 5, 375-87	1.4	21
47	Anticholinergics in adult-onset focal dystonia. <i>Canadian Journal of Neurological Sciences</i> , 1982 , 9, 313-9	1	42
46	Pergolide in late-stage Parkinson disease. <i>Annals of Neurology</i> , 1982 , 12, 243-7	9.4	57
45	Alcohol and Parkinson disease. <i>Annals of Neurology</i> , 1982 , 12, 254-6	9.4	39
44	Iris pigmentation in idiopathic dystonia. <i>Annals of Neurology</i> , 1982 , 12, 585-6	9.4	2
43	Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. <i>Neurology</i> , 1982 , 32, 1335-46	6.5	377
42	Lessons learned: neuroprotective trials in Parkinson's disease265-279		
41	The Clinical Spectrum of Functional/Psychogenic Dystonia217-223		
40	Acute akathisia3-19		3
39	Measuring quality of life in progressive supranuclear palsy52-59		1
38	Movement Disorders: an Overview3-19		1
37	Miscellaneous Drug-Induced Movement Disorders430-441		1
36	The Pharmacology of Typical and Atypical Antipsychotics55-71		2
35	Acute Drug-Induced Dystonia72-102		3

34	Drug-Induced Parkinsonism103-139	6
33	Acute Drug-Induced Akathisia140-173	2
32	The Ontario Neurodegenerative Disease Research Initiative	6
31	Visual QC Protocol for FreeSurfer Cortical Parcellations from Anatomical MRI	1
30	REM Sleep Behavior Disorder and Neurodegenerative Disorders246-256	
29	Restless Legs Syndrome and Akathisia in Parkinson's Disease333-345	
28	Assessment of Non-Motor Features of Parkinson's Disease: Scales and Rating Tools111-125	
27	Neuropsychologic Features of Parkinson's Dementias145-152	
26	Sexual Dysfunction296-303	
25	Anatomy and Physiology of Limbic System Dysfunction in Parkinson's Disease70-78	
24	Bladder Dysfunction in Parkinson's Disease and Other Parkinsonism274-283	0
23	Orthostatic Hypotension in Parkinson's Disease284-295	
22	Prospects for Neuroprotective Therapies that can Modulate Non-Dopaminergic Features in Parkinson's Disease455-461	
21	Surgery for Non-Dopaminergic and Non-Motor Features of Parkinson's Disease409-415	
20	Olfactory Dysfunction304-314	
19	Functional Organization of the Basal Ganglia: Dopaminergic and Non-Dopaminergic Features56-69	
18	Functional Anatomy of the Motor and Non-Motor Circuitry of the Basal Ganglia32-55	
17	Animal Models of Parkinson's Disease: The Non-Motor and Non-Dopaminergic Features79-92	

16	Neuropathology of Dementia in Parkinson's Disease	153-162	
15	Gastrointestinal and Swallowing Disturbances in Parkinson's Disease	257-273	
14	Gait, Postural Instability, and Freezing	261-373	1
13	Neuropathologic Involvement of the Dopaminergic Neuronal Systems in Parkinson's Disease	7-14	1
12	Clinical Trial Measures of the Non-Motor Features of Parkinson's Disease	126-133	
11	Treatment of Dementia Associated with Parkinson's Disease	163-169	
10	Neuroleptic-Induced Tardive Dyskinesia Variants	257-284	5
9	Commentary: Is Tardive Dyskinesia Disappearing?	302-310	1
8	Dyskinesia Induced by Levodopa and Dopamine Agonists in Patients with Parkinson's Disease	313-350	1
7	Antiepileptics	408-429	2
6	Rating Scales for Movement Disorders	20-29	1
5	The Dopaminergic and Non-Dopaminergic Features of Parkinson's Disease	1-6	1
4	Non-Dopaminergic Pathology of Parkinson's Disease	15-31	3
3	Effects of Exercise on Basal Ganglia Function in Parkinson's Disease and Its Animal Models	416-431	1
2	Movement Disorders and Dopaminomimetic Stimulant Drugs	351-370	
1	Spontaneous Movement Disorders in Psychiatric Patients	30-52	